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SOMMARIO 
I dati scientifici suggeriscono che entro il 2030, fino al 58% della 
popolazione adulta mondiale sarà sovrappeso o obesa [1]. L’insorgenza di 
questa patologia [2] non è solo dovuta alla mera componente alimentare, 
infatti, una serie di elementi che spaziano dallo stile di vita alla genetica 
contribuiscono al suo sviluppo [3–5]. L’obesità è di frequente associata al 
deficit della vitamina D (Vit. D) [6,7] e la genetica è spesso stata invocata 
per fornire una spiegazione a questa associazione [8], tuttavia, differenze 
nell’esposizione solare e nel metabolismo della vitamina D sono 
ugualmente responsabili [9]. Recentemente, i lipidi ed in particolare gli 
sfingolipidi, come le ceramidi (Cers) e le sfingomieline (SMs), vengono 
sempre più spesso indicati come responsabili, non solo dell’aumento 
dell’attività infiammatoria [10,11], ma anche dello sviluppo di patologie 
cardiovascolari e diabete di tipo 2 [12–14], due condizioni comunemente 
osservate nei soggetti obesi. Il nostro studio è stato motivato dal ruolo 
cruciale che gli sfingolipidi (SLs) svolgono nelle patologie associate 
all’obesità e dall’associazione esistente tra obesità, dislipidemia e deficit 
della Vit. D. Il nostro progetto è stato quindi focalizzato alla definizione dei 
profili degli sfingolipidi circolanti nell’uomo, caratterizzato dalla presenza di 
questa triade di condizioni, in modo tale da fornire suggerimenti per 
l’identificazione di nuovi biomarker che potessero essere introdotti nella 
pratica clinica. 
Per definire il profilo sfingolipidico durante l’obesità, la dislipidemia ed il 
deficit associato di Vit. D, i sieri di 23 soggetti normopeso normolipidemici 
(NWNL), 46 soggetti normopeso dislipidemici con deficit della Vit. D 
(NWDL) e 60 soggetti obesi dislipidemici con deficit della Vit. D (ODL) sono 
stati analizzati tramite un duplice approccio, caratterizzato dall’utilizzo di 
due tecniche complementari, l’HPTLC-Primuline profiling e l’analisi LC-MS. 
Inoltre per definire i profili sfingolipidici nel contesto dell’adattamento 
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differenziale ad alta quota, i sieri di 59 bambini dislipidemici, con deficit 
della Vit. D e provenienti da un altipiano Argentino (3775 mt s.l.m) sono 
stati analizzati tramite LC-MS. I soggetti sono stati divisi, in base al 
percentile del loro BMI, in quattro gruppi: 7 sottopeso (UW), 30 normo peso 
(NW), 13 sovrappeso (OW) e 9 obesi (O). 
Le differenze nei profili sfingolipidici identificate nei soggetti NWNL e ODL 
provenienti dall’Arabia Saudita sono causate non solo dall’obesità ma 
anche dall’associazione con la dislipidemia e con il deficit di Vit. D. Le 
differenze di genere determinano invece alterazioni dei profili sfingolipidici 
che sono indipendenti dalla dislipidemia e dal deficit della Vit. D. Nel 
confronto NWDL vs. ODL sono state identificate delle alterazioni nei profili 
di specifiche catene di SMs, Cers e diidrosfingomieline (dhSMs) 
strettamente associate alla sola obesità, le quali si ritiene possano essere 
correlate ad un aumento del rischio di sviluppare patologie legate 
all’obesità. 
Le alterazioni osservate nei soggetti che vivono ad alta quota, dislipidemici 
e con deficit della Vit. D hanno permesso di confermare i risultati relativi 
all’associazione tra SLs, dislipidemia e deficit della Vit. D ottenuti nei 
soggetti provenienti dall’Arabia Saudita. L’analisi di questi soggetti ha 
inoltre permesso di identificare profili sfingolipidici caratteristici, associati al 
BMI e dipendenti dall’adattamento all’ipossia. 
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ABSTRACT 
Research studies indicate that up to 58% of the world adult population will 
be overweight or obese by 2030 [1]. Obesity is not only related to food 
intake, but factors such as lifestyle and genetic background contribute to its 
onset [3–5]. This disease [2] is commonly associated with vitamin D (Vit. D) 
deficiency [6,7], and genetic associations have been identified to explain 
this link [8]; however, differences in dietary intake, sun exposure, or Vit. D 
metabolism are also involved [9]. Moreover, along with Vit. D deficiency, 
lipids, and particularly sphingolipids (SLs) as ceramides (Cers) and 
sphingomyelins (SMs) have been described as involved, not only in 
increasing inflammation [10,11], but also in the development of 
cardiovascular disease and type two diabetes [12–14], two common 
conditions observed in obese subjects. Given the pivotal role of SLs in 
obesity associated co-morbidities and the association of Vit. D, 
dyslipidemia and obesity, our study was aimed at profiling circulating SLs in 
human subjects under these conditions, in order to provide hints for the 
identification of new biomarkers to be introduced in clinical settings. 
To define human SLs profile in obesity, dyslipidemia, and Vit. D associated 
deficiency, sera from 23 normal-weight normolipidemic (NWNL), 46 normal-
weight, dyslipidemic, Vit. D deficient (NWDL) and 60 obese dyslipidemic, 
Vit. D deficient (ODL) Saudi Arabian subjects were analyzed with a dual 
approach, characterized by the use of two complementary techniques: the 
HPTLC-Primuline profiling and the LC-MS analysis. Furthermore, to define 
SLs profiles in the context of human adaptation to high altitude hypoxia, 
sera from 59 Vit. D deficient dyslipidemic children living at high altitude 
were analyzed by LC-MS. Children were grouped based on their BMI 
percentiles in 7 underweight (UW), 30 normal-weight (NW), 13 overweight 
(OW) and 9 obese (O). 
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SLs profile analysis of NWNL and ODL Saudi Arabian subjects displayed 
differences in total Cer and total SM caused by dyslipidemia and vitamin D 
deficiency, whereas specific Cers, and SMs acyl chains characterize obese 
subjects, only. Gender differences were found in SLs profiles independently 
from dyslipidemia and Vit. D status. Obesity-associated Cers, SMs, and 
dihydrosphingomyelins (dhSMs) specific acyl chains were identified in the 
NWDL vs. ODL comparison independently from dyslipidemia and Vit D 
status, and are thought to be drivers of increased risk of developing 
obesity-associated morbidities. 
The analysis of SLs profiles from dyslipidemic children with Vit. D 
deficiency allowed to confirm the results of Saudi Arabian subjects 
regarding SLs association with dyslipidemia and associated Vit. D 
deficiency. Furthermore, SLs profile analysis led to the identification of a 
characteristic SLs portraits associated with BMI and related to hypoxia 
metabolic adaptation.  
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1. OBESITY 
The debate over the term obesity and its implications engaged physicians 
and general public information during the last three decades. It has been so 
challenging to decide whether it was only a condition or an illness that only 
in 2013 the American Medical Association recognized it as a disease [15], a 
decision already been made by the National Institute of Health since 1998 
[16]. This peculiar pathology is a growing-worldwide emergency, estimated 
to affect more than 58% of adults by 2030 [1], so crucial that its burden and 
impact over the worldwide population generated the term “globesity” [17]. 
Nowadays, obesity and overweight are defined by the World Health 
Organization (WHO) as the excessive or abnormal deposition of fat with a 
risk for health [18].  
Obesity can be measured using anthropometrical parameters such as 
skinfold thickness, waist circumference (WC), waist to hip ratio and BMI, or 
can be assessed employing technical methods as X-ray absorptiometry or 
densitometry. 
Skinfold thickness measures subcutaneous adipose tissue in the triceps 
and subscapular area and is used in addition to BMI to evaluate obesity 
providing a more accurate assessment of body fat [19,20]. The waist 
circumference measurement (WC) is the easiest way to determine central 
obesity, and some reports identified WC as a significant predictor of 
obesity-related diseases, particularly of cardiovascular diseases (CVD) 
[21,22]. The waist to hip ratio is another parameter used to assess and 
predict cardiovascular risk in obese patients because it is a surrogate 
marker of visceral obesity, and it has been shown to perform better in risk 
prediction than BMI alone [23,24]. 
From the technical point of view, dual-energy X-ray absorptiometry 
provides measurements that permit to infer the body composition in 
humans [25], while densitometry, based on Archimedes’ principle of water 
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displacement, provides an estimation of total body fat and lean tissues 
content [26]. Methods based on anthropometrical parameters are 
commonly used to assess the risk of developing obesity-associated 
diseases, however, the technical measurements based on densitometry 
and X-ray absorptiometry are more focused on the “quantification” of 
adipose tissue and are therefore a better indication of obesity per se. 
Independently from their utility in the classification of obese patients, the 
two techniques are challenging to perform, time-consuming, expensive, and 
require sophisticated instrumentation. As a result, due to its simplicity and 
effectiveness in classifying subjects, BMI is the most employed system for 
the screening of overweight and obesity. 
Current guidelines from WHO [18] and the Center for Disease Control and 
Prevention (CDC) [27] define obesity using BMI, obtained as the ratio 
between the weight (Kg) and the square of the height (m). This simple 
measure permits to classify adults population into four main different 
classes: underweight (UW) (BMI< 18.5 kg/m2), normal weight (NW) (18.5-
24.9 kg/m2), overweight (OW) (25-29.9 kg/m2) and obese (O) (BMI> 30 
kg/m2). In turn, obesity can be further organized in five main classes: type 1 
obesity (30-35 kg/m2), type 2 (35-40 kg/m2), type 3 (BMI> 40kg/m2), type 4 
(BMI> 50kg/m2) and type 5 (BMI> 60 kg/m2). Asian population usually have 
lower BMI cut-off for obesity and overweight [28]. For children, the definition 
of obesity relies not only on their intrinsic BMI but also on their age, gender, 
and their corresponding percentile in the population growth chart. Children 
whose BMI falls in the 5th percentile are considered UW, NW if BMI falls in 
the 5th to the 85th, OW if BMI falls from the 85th to the 95th, and O if their 
BMI is located above the 95th percentile [29].  
Following this classification in 2016, the WHO concluded that since 1975, 
the global prevalence of obesity and overweight has tripled, affecting more 
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than 1.9 billion adults, more than 340 million children aged 5-10 and more 
than 41 million children under the age of five [18].  
The increase in adiposity and specifically, its excess is an established risk 
factor associated with several causes of mortality [30]. During obesity, the 
whole organism develops an altered metabolism causing an increased risk 
of developing CVD, type 2 diabetes mellitus (T2DM) and many types of 
cancer.  
Basically and historically, obesity is the result of an imbalance between 
caloric intake and energy expenditure, and thus the increase in food intake 
and the reduction in physical activity are to blame for the increase in weight 
gain [31–33].  
 
Diet  
Human experimental studies regarding food consumption and energy 
intake demonstrated that an increase in the amount of available food 
resulted directly into voluntary increased energy intake [34]. Consistently, a 
meta-analytic review found that doubling food portions results in a 35% 
increase in energy intake in humans [35]. 
In the last forty years, diet composition and food availability have changed 
worldwide. These changes reflect the pro-capita food availability. As an 
example, caloric intake in the U.S. from 1971 to 2004 increased 
respectively of 335 calories per day for women and 168 calories per day for 
men [36]. The idea that an increased energy intake overcoming energy 
expenditure could be the driver of obesity led to the creation of a model to 
predict body weight gain [37]. This model predicts that and increase in 100 
kJoule per day (23.9 cal) will lead to an increase of 1kg of body weight in 
approximately three years. A recent study conducted in 2015, analyzing the 
food energy supply from 69 different countries, demonstrated that in 56 
nations, the increment in body weight is associated with an increase in food 
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energy supply [38]. Studies have confirmed that this trend towards global 
caloric intake increase positively correlates with the increase in weight gain 
observed in different populations worldwide [39,40].  
These studies confirmed that the availability of more food and specifically of 
more caloric food result in increased food energy intake, that is a driver of 
obesity.  
As previously stated, the cause of obesity seems to be simple: it is the 
result of a prolonged period of caloric energy intake, overcoming the energy 
requirements of the organism. 
Nevertheless, this direct association has been revised by several studies, 
suggesting that genetics, gut microbiota, and other associated illness are 
also involved in the increased risk of developing obesity. 
Genetic causes 
People exposed to similar habits (sedentary life) and diets (western diet) 
does not develop the same response in term of weight gain, suggesting 
that genetic background contribute to regulate obesity. Studies involving 
monozygotic and dizygotic twins initially approached hereditability of BMI. 
Those studies concluded that body fat-mass had a vast concordance in 
monozygotic twins (70-90%), while a lower concordance was identified for 
dizygotic twins (35-45%) [41,42]. Other studies conducted on adoptive 
families confirmed the correlation of adoptees’ BMI with biological parents’ 
BMI, but not with BMI from adoptive parents [43].  
Furthermore, the observation that BMI is, to some extent inheritable [44] 
supported the idea of genetics drivers behind obesity.  
Nowadays, only a few rare genes have been identified as causative for the 
increase in BMI. These genes control the coding of different components of 
the leptin, proopiomelanocortin and melanocortin signaling [45,46].  
The signaling of leptin takes place in the hypothalamus, the “nutrient-
sensing” organ, in which leptin derived from adipose tissue stimulates 
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neurons in the arcuate nucleus, inhibiting hunger and stimulating satiety 
[47]. Similarly, melanocortins (a group of peptide hormones) acts in the 
arcuate nucleus of the hypothalamus by binding melanocortin receptor 4 
(MC4R) in the food intake regulation [48]. Despite these interesting results, 
it is believed that the “genetics of obesity” does not rely only on monogenic 
cases, but rather is based on the interaction of a multitude of different 
genes with smaller effect sizes. 
Genome-wide association studies provided useful information regarding the 
association between single-nucleotide polymorphisms and obesity-
associated traits. Specifically, more than 140 genetic chromosomal regions 
are related to obesity, and gene expression related to adiposity is highly 
enriched in the central nervous system [49]. More recently, another 
genome-wide association studies identified 227 genetic variants related to 
different biological pathways (food sensing, adipocyte differentiation, insulin 
signaling, lipid metabolism, muscle and liver, gut microbiota) as relevant for 
the development of polygenic obesity [50]. The first and most interesting 
identified variants were related to fat mass and obesity-associated gene 
(FTO), for which several studies showed increased heterozygotes and 
homozygotes risk for developing obesity and T2DM [51,52].  
Gut microbiota 
The human gastrointestinal tract and specifically the colon is highly 
populated in bacteria, viruses and fungi [53]. The resulting ecosystem, 
commonly called gut microbiota, is exposed since birth to several factors 
influencing its development (type of birth, diet, use of antibiotics) [54]. 
Several evidences highlighted the importance of gut microbiota in 
supporting different processes in the gastrointestinal tract, ranging from 
digestive process [55], vitamin synthesis [56] protection from pathogens 
[57] to modulation of the immune system [58]. Gut microbiota contributes to 
human health, and changes in its composition, called dysbiosis, can 
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contribute not only to the development of diseases but also to the 
development of obesity. As an example, germ-free obesity-resistant mice 
develop obesity if they are transplanted with microbiota from a healthy 
donor, increasing the overall energy intake from diet [59]. Qualitative 
variations also account for obesity gut microbiota profile. Obese subjects 
are characterized by reduced diversity in the components of their gut 
microbiota, and moreover, they present increased Firmicutes/Bacteroides 
ratio [60,61]. Data indicating an increased prevalence of Firmicutes at the 
expense of Bacteroides were further confirmed in feces from obese mice 
[62]. 
One of the explanations proposed to understand the role of gut microbiota 
in obesity development relies on the capacity of bacteria to ferment 
polysaccharides coming from the diet that generally would not be digested 
by humans [63]. As a result of dietary fiber fermentation, short-chain fatty 
acids (SCFA) [63] are produced, quickly uptaken from enterocytes, and 
transported into circulation. The increased absorption of SCFA due to 
altered fermentation results in both an increase of triglycerides (TG) 
synthesis and an increase in energy uptake from the diet [64]. The gut 
microbiota influences not only nutrient uptake but also trigger metabolic 
inflammation, exacerbating the chronic low-grade inflammation and insulin 
resistance seen in obese patients [65]. Lipopolysaccharides from gram-
negative bacteria, commonly found in the gastrointestinal tract, are known 
to be activators of Toll-like receptor 4 (TLR-4) [66]. In turn, TLRs are known 
to upregulate inflammatory response stimulating the production of cytokines 
and chemokines. 
Associated illness 
Physical and mental illnesses, as well as medications that are used to treat 
them, are also known to increase the risk of developing obesity. In this 
context: hypothyroidism [67], Cushing's syndrome [68] the use of 
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antidepressant [69], corticosteroids [70], and eating disorders [71] have 
commonly been linked to obesity. 
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2. VITAMIN D 
Vitamin D is a group of fat-soluble steroids mainly represented in plants by 
vitamin D2 (ergocalciferol) and in animals by vitamin D3 (cholecalciferol) 
[72]. Their active forms are responsible for multiple biological processes, of 
which the most prevalent is the intestinal uptake of calcium [73] and 
phosphate [74]. Natural sources of Vit. D in humans are related to both sun 
exposure and diet intake, with the first accounting as the primary source 
and the second covering up to 20% of the required daily Vit. D intake [75]. 
During sun exposure, the 7-diidrocholesterol present in the skin, between 
stratum basale and stratum spinosum, is converted by UVB radiation (290-
315 nm) into pre-vitamin D [76].  
Pre-vitamin D in the skin it is not active and requires two subsequent 
hydroxylations steps to develop the fully active form. Hydroxylation of Vit. D 
is provided by two distinct hydroxylase (CYP2R1 and CYP27B1) [77]. The 
first, located in the liver, hydroxylates Vit. D in position 25 and produces the 
25-hydroxyvitamin D (25-D), whereas the latter is present in the proximal 
renal tubule of kidneys and produces the biologically active form 1,25-
dihydroxyvitamin D (1,25-D). Vit. D degradation takes place in the kidneys 
as a result of another hydroxylation (hydroxylase CYP24A1) acting on both 
25-D and 1,25-D, causing the formation of 24,25-dihydroxyvitamin D 
(24,25-D) [78]. Vit. D levels in serum are generally estimated through the 
quantification of its more abundant and inactive form 25-D [79]. 
The biological effects of Vit. D (e.g., mineral homeostasis, cell 
differentiation/proliferation) [80] are mediated by its binding to nuclear Vit. D 
receptor (VDR), a ligand-activated transcription factor that controls gene 
expression. After being activated by its ligand, VDR heterodimerizes with 
the retinoid X receptor and in turn, recruits coregulatory complexes to 
modify gene expression [81]. Even though responses are tissue-specific 
and biological effects range from growth control to immune system and 
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functional control of cellular activity, the main biological effect undertaken 
by Vit. D is the regulation of calcium homeostasis, specifically obtained by 
increasing calcium absorption in the small intestine and calcium resorption 
from bones [82]. Calcium absorption in the small intestine is finely regulated 
by increasing gene expression of several calcium-associated molecules: 
TRPV6 (enterocytes membrane calcium transporter), calbindin-D9K 
(facilitates calcium transport through the enterocytes and buffers high levels 
of calcium-induced cytotoxicity), CaATPase and PMCA1b (mediating the 
extrusion of calcium from the basolateral membrane of enterocytes). 
Furthermore, when normal calcium levels are not reached, Vit. D acts 
synergically with parathyroid hormone (PTH) to stimulate both osteoclast 
differentiation in bones for calcium resorption [83,84] and calcium 
reabsorption from the distal renal tubule (increase expression of genes 
controlling calcium transporter TRPV5 and calbindin-D9K) [85]. 
2.1. Vitamin D deficiency  
The paramount role of Vit. D in the regulation of calcium homeostasis and 
bone remodeling results in the maintenance of correct Vit. D levels not only 
during human development but also in adults for the preservation of bone 
health and cellular homeostasis. The role of Vit. D deficiency in bone 
homeostasis was at first uncovered in children with rickets [86], 
nevertheless several other associated illnesses have been linked to this 
status and in particular, infectious diseases [87], autoimmune disorders 
[88], cancer [89], cardiovascular diseases [90] and obesity [7,91,92] are 
thought to be affected by Vit. D deficiency. 
There is not a worldwide consensus on correct Vit. D levels, and even 
though there is a general agreement in defining Vit. D severe deficiency as 
serum levels of 25-D are below 10-12 ng/ml (25/30 nmol/l), several 
differences emerge between guidelines from different groups and nations in 
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the definition of Vit. D insufficiency or sufficiency. Vitamin D Council 
denotes as sufficient for humans, a level of Vit. D superior to 100nmol/l or 
40ng/ml. On the contrary, the Scientific Advisory Committee on Nutrition 
starts to consider Vit. D sufficiency at lower levels (30nmol/l or 12ng/ml). 
For the Endocrine Society, the International Osteoporosis Foundation and 
the American Geriatrics Society serum 25-D sufficiency sits over the cut-off 
of 75nmol (30ng/ml), while for the Institute of Medicine and American 
Academy of Pediatrics the adequacy of Vit. D comes from levels higher 
than 50nmol (20ng/ml). The definition of Vit. D sufficiency is, even more, 
complicate in children. Where the European food safety authority draws a 
line for sufficiency at levels of at least 50nmol/l (20ng/ml), the Scientific 
Advisory Committee on Nutrition reports lower lever of sufficiency (30nmol/l 
or 12ng/ml).  
The only standard global-accepted level for Vit. D deficiency is, therefore, 
the cut off identifying the Vit. D severe deficiency (Vit. D levels lower than 
10-12 ng/ml). The lack of harmony in the definition of Vit. D sufficiency or 
insufficiency between different guidelines significantly affects the 
prevalence reported from different studies conducted in different locations. 
Additionally, the fragmentation of reviews coming from different countries, 
the use of different cohorts, and the incomplete picture of Vit. D 
determinants (UVB exposure, dietary intake) severely hamper the 
recognition of a global Vit. D prevalence.  
Nowadays, data coming from reviews on global Vit. D status indicates 
widespread Vit. D deficiency, and even though data were produced ten 
years ago; some consistent results are showing a higher prevalence of 
deficiency in Asia, Middle East and Africa in both children and adults [93]. A 
systematic review [94] from 2014 describes the best picture for Vit. D 
deficiency worldwide. However in this case, authors, analyzing 103 national 
reports, indicate a widespread lack of data from several countries, the use 
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of different Vit. D detection method and different cohorts, suggesting that 
the definition of a global prevalence for Vit. D deficiency is far to be defined. 
Vit. D deficiency arise from a multitude of causes, including inadequate 
food intake and sun exposure, liver and kidney chronic diseases [95,96], 
obesity [97,98], pathologies resulting from malabsorption (celiac disease, 
inflammatory bowel diseases) [99] and treatment with medication that 
induce hepatic P450 in degrading Vit. D (carbamazepine, dexamethasone, 
nifedipine) [100].  
In the last 20 years and more precisely from 2000, Vit. D deficiency and its 
relation with obesity become more interesting for the scientific community. 
Published papers regarding obesity and Vit. D, in fact, increased 
significantly from 14 in 2000 to 565 in 2018, suggesting a strict association 
between the two phenomena but also an increased concern over the global 
effects of these two pandemics. 
2.2. Vitamin D deficiency and obesity 
Researchers have found a consistent association between low serum vit.D 
concentration and obesity [101–104]. To our knowledge, the first study 
identifying a link between obesity and Vit. D was conducted in 1977 by 
Teitelbaum et al. [105]. The authors noticed that obese patients who 
underwent small intestine bypass for the treatment of obesity had low levels 
of Vit. D and concluded that the treatment resulted in a transient deficiency 
of circulating Vit. D. Apart from the interest of the study, the link between 
obesity and Vit. D deficiency was a result of the effects of surgery, and it 
was only in 1981 that Compston and colleagues were able to demonstrate 
that obese subjects have a higher risk of developing Vit. D deficiency than 
normal-weight subjects [106]. 
Several other studies have been conducted over the years, in 1985 Bell et 
al. [107], confirmed the reduction of 25-D seen in obese patients by 
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Compston but identified in the same patients an increase in 1,25-D, the 
active form of Vit. D. In 1988 a work from Liel et al. [108] identified the 
same reduction in 25-D in obese patients but not the increase in 1,25-D. 
More recently, other studies identified the same dependency between 
obesity and Vit. D. In 2010, a work by Herranz Antolín S [109] and 
colleagues found that morbidly obese patients have lower mean levels of 
Vit. D (16.6 ng/ml vs. 21.9 ng/ml) and higher prevalence of Vit. D deficiency 
(80% during obesity, 40% in non-obese) when compared to normal-weight 
subjects. Further supporting these results, a bi-directional genetic study by 
Karani S. Vimaleswaran and colleagues identified, in 21 adult cohorts 
(42,024 participants), an association between serum Vit. D levels and BMI. 
Their study indicated that for every increase in one BMI point (1kg/m2), a 
1.15 % decrease in Vit. D levels is seen, confirming in a large cohort the 
detrimental effects of obesity on Vit. D status. 
Multiple hypotheses have been formulated to explain the decrement of Vit. 
D in obese subjects, specifically regarding dietary intake, reduce bio-
synthesis, altered metabolism/catabolism/intestinal absorption, or adipose 
tissue distribution.  
Vitamin D dietary intake was shown to be lower in obese men compared to 
normal-weight but not in obese women [110]. In obese children aged 1-3 
compared to normal-weight age-matched controls, a two-fold decrease 
(although not statistically significant) in dietary intake of Vit. D was seen 
[111]. Similarly, a decrement in dietary intake was also seen in obese 
children and normal-weight children aged 1-5, resulting in an 80% of Vit. D 
deficiency prevalence for the obese group and 70% for the normal-weight 
[112]. Nevertheless, lower Vit. D status have been identified in obese 
women compared with normal-weight despite higher Vit. D intake [113], 
suggesting that other underlying factors also need to be taken into account 
for Vit. D deficiency. 
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Reduced synthesis from reduced skin exposure or altered skin biosynthetic 
capacity have also been proposed as causes for obesity-related Vit. D 
deficiency. In the first case, differences in sun exposure have been 
proposed to explain differences in Vit. D biosynthesis. Authors found that 
people with a BMI> 30kg/m2 were less willing to expose their bodies to the 
sun when compared to people whose body mass index (BMI) was lower 
than 30 kg/m2 [114]. In the second case, altered skin biosynthetic capacity 
was supposed to be causative in the reduction of levels of Vit. D during 
obesity, nevertheless, 7-dihydrocholesterol was found to have similar levels 
in obese and normal-weight patients as well as its conversion to Vit. D 
[115], suggesting that Vit. D deficiency is not caused by reduced 
biosynthesis. 
Both the altered metabolism and catabolism of Vit. D were proposed as 
causative in obesity-associated Vit. D deficiency. Subcutaneous human 
adipose tissue expresses the three hydroxylases required for the formation 
of 25-D (precursor form), 1,25-D (active form) and 24,25-D (degradation), 
respectively. Moreover, both the 25-hydroxylase (CYP2J2) and the 1α-
hydroxylase (CYP27B1) show reduced expression in obese adipose tissue 
[116], supporting the idea that altered metabolism for Vit. D is present in 
adipose tissue of obese patients. Furthermore, the presence of the 
hydroxylase CYP24A1, responsible for the inactivation and sequent 
degradation of 25-D, has been documented in human adipocytes [117], and 
the expression of its mRNA is strongly induced  in vitro by incubation with 
1,25-D, suggesting that adipose tissue can actively metabolize Vit. D. 
Altered intestinal absorption was also indicated as a possible explanation 
for Vit. D deficiency during obesity. As demonstrated by Teitelbaum et al. 
[105] in 1977, low levels of 25-D were present in obese patients after small-
intestine bypass, suggesting decreased intestinal Vit. D assimilation. This 
article paved the way for intensive studies regarding bariatric surgery, Vit. D 
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levels and risk of bone diseases [118–121] — however, the procedure 
induced the resulting 25-D deficiency, and today there is no evidence in Vit. 
D malabsorption during obesity.  
By being fat-soluble, when Vit. D (radiolabeled) is administered to mice, it 
quickly accumulates in the adipose tissue, and it has been observed that 
one month after radiolabeled treatment, Vit. D is still present in the same 
tissue, indicating that its release is slow and prolonged [122]. Blum M et al. 
identified a positive correlation between human serum Vit. D levels and 
adipose tissue, suggesting the storage of Vit. D in adipose tissue [123]. 
In 2012, a work by Drincic AT and colleagues provided an alternative 
explanation by demonstrating that when 25-D levels of obese subjects were 
corrected by body size, the difference in Vit. D levels with normal-weight 
were in such a way abolished. Their model, called volumetric dilution, 
asserted that any increase in Vit. D has to be distributed not only in serum 
but also in total body fat. As an example, if the whole body fat mass is 
doubled as in obese compared to a normal-weight subject, the increase, 
due to any input, in serum Vit. D levels of obese subjects would be half of 
the size [124]. 
Even though the association between these phenomena is today 
acknowledged, and several possible explanations have been identified, a 
causal relationship is still lacking, and further studies are mandatory not 
only to identify the pathogenesis of this relationship but also to assess its 
associated risk. 
2.3. Vitamin D deficiency and dyslipidemia 
Vitamin D deficiency does not only correlate with obesity-specific criteria 
like BMI, adiposity, or subcutaneous adipose tissue, but also with other 
obesity-related parameters commonly identified in obese subjects as 
changes in lipidic serum profile, called dyslipidemias. 
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In the context of abnormal serum lipid profiles, dyslipidemias are usually 
observed in the 60-70% of obese subjects [125]. These subjects are 
characterized by increased serum levels of TG, total cholesterol (TC), 
VLDL, slightly increased LDL-C, and decreased levels of HDL-C [126]. 
In a small cohort of 150 Indian subjects, Chaudhuri and colleagues [127] 
were able to identify high levels of TC, LDL, TG, and low levels of HDL-C in 
Vit. D deficient subjects. Consistently, in 2012, a work by Ponda and 
colleagues [128], found that, when compared to Vit. D deficient patients, 
those with correct levels had lower TG, TC, LDL-C, and higher HDL-C 
levels. However, the authors found that when Vit. D levels are raised in Vit. 
D deficient subjects, there is an increase in HDL-C levels and total TC while 
LDL-C levels remain stationary, suggesting that Vit. D supplementation 
may not result in an improvement of all serum lipid parameters. 
Similarly, while working on Vit. D and CVD risk factors, Jiang et al. [129] 
confirmed data for Vit. D deficiency from Chaudhuri and Ponda, showing 
that Vit. D levels negatively correlate with LDL-C and TG and positively with 
HDL-C, furthermore confirming that Vit. D deficiency results in a poorer lipid 
profile. Accordingly to previous reports, Wang et al. [130] identified a 
negative association between Vit. D level, TG and LDL-C and recently, a 
work by Sun X [131] showed that serum Vit. D levels are inversely 
associated with triglycerides, Apolipoprotein B (ApoB), with the ratio of LDL 
cholesterol/HDL cholesterol, and ApoB/ApoA-1. 
Vit. D affects serum lipid profiles through mechanisms that are not fully 
understood and includes: the suppression of parathyroid hormone secretion 
[132], the intestinal absorption of calcium [133], the modulation of beta cells 
activity and insulin resistance [134], the regulatory effect of Vit. D on 
adipose tissue differentiation and Vit. D suppression of lipoprotein lipase 
[135,136]. 
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Regardless of the causes that are not clear and will require further studies, 
increasing evidences indicate that high serum Vit. D levels are associated 
with a more favorable serum lipid profile [136–138].  
Data from literature raise the point that Vit. D deficiency is pandemic and 
acts detrimentally on both obesity and obesity-associated dyslipidemia. 
Studies should, therefore, address this triad of disorders together in order 
to asses and fully entangle this intricate metabolic flux. 
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3. SPHINGOLIPIDS 
3.1. Sphingolipid synthesis  
Sphingolipids are molecular components of membranes responsible for 
their homeostasis. Changes in lipid composition can influence not only 
membrane structure but also receptors organization and function. 
Ceramide, sphingosine (Sph), and sphingosine-1-phosphate (S1P) are 
known to act as signaling molecules and are involved in the regulation of 
cell growth, differentiation, senescence, and apoptosis [139–142]. 
The SLs metabolic pathway is an intricate structure that envelopes simple 
molecules like Cers and a multitude of complex glycosphingolipids in which 
Cers represents the molecular core of the biosynthesis and catabolism of 
SLs. Ceramide levels in cells can be associated with de novo synthesis or 
hydrolysis of complex sphingolipids resulting from degradation of 
glycosphingolipids (GSLs) or hydrolysis of sphingomyelins [143,144]. In the 
de novo pathway, serine and palmitoyl-CoA are condensed by serine 
palmitoyltransferase (SPT) to produce 3-ketodihydrosphingosine, which in 
turn is reduced to dihydrosphingosine (sphinganine) [145]. Cer synthases 
(CerS1-6), N-acylate the sphinganine to produce dihydroceramide (dhCer) 
that undergo desaturation by dihydroceramide desaturase (DEGS) to finally 
generate Cers. By this pathway, several Cers with different acyl chain 
lengths can be produced, depending on the different CerS isoforms, from 1 
to 6, that have specific preference for different chain length fatty acyl-CoAs 
[146]. The biological role of products from different Cers isoforms 
generating Cers with different acyl moiety remains so far undisclosed. The 
produced Cer can undergo three different pathways: it can be 
phosphorylated to Ceramide-1-phosphate (C1P) [147], converted to GSLs 
[148,149], or can be used to synthesize sphingomyelins [150]. Cer is also 
produced from the breakdown of complex glycosphingolipids through the 
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sequential removal of the hydrophilic portions of GSLs by specific 
hydrolases producing galactosylceramides (GalCer) or glucosylceramides 
(GlcCer), which in turn can be hydrolyzed by specific galactosidase or 
glucosidases to produce ceramide [151].  
At variance, the SM hydrolysis is controlled by five main types of 
sphingomyelinases (SMases): lysosomal acid SMase, neutral SMase (Mg2+ 
dependent), alkaline SMase or zinc-dependent SMase with different 
subcellular localization and pH. Their action on SMs determines the release 
of Cer and phosphocholine [152]. 
Once released, Cer can undergo degradation as a result of acid, alkaline, 
and neutral alkaline ceramidases (CDases) regulated by pH and subcellular 
localization. Those enzymes remove the fatty acid (FA) from Cer, producing 
free sphingosine (Sph). The latter can return to the SLs pathway or be 
phosphorylated by the action of specific kinases (Sphingosine kinases 1-2) 
to S1P [153]. S1P can be dephosphorylated to Sph by specific S1P 
phosphatases or can be metabolized by S1P lyase, resulting in the release 
of ethanolamine phosphate and hexadecenal [154]. The precise 
compartmentalization of these molecules regulates SLs synthesis: the initial 
step occurs at the cytosolic side of the ER but also on ER perinuclear 
membranes or mitochondrial associated membranes (Figure 1). The 
second and third steps occur in the Golgi, in which more complex 
molecules are synthesized and transported to the plasma membrane 
through vesicular trafficking. From the plasma membrane, SLs can be 
recirculated through the endosomal pathway. SM and GlcCer are 
metabolized to Cer in the lysosomal compartment by SMases and 
glucosidases, while Cer is degraded by acid CDase to form Sph. The latter, 
thanks to its positive charge, can leave the lysosome and move in the 
cytosol between membranes becoming available for recycling. This precise 
compartmentalization reinforce the concept that those molecules are not 
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merely structural component but actively participate to biological processes 
[155–157] and their dysregulation can impact not only on membrane 
structure dynamics but also on signaling pathways involved in metabolic 
diseases.  
Figure 1. Sphingolipids biosynthesis and intracellular trafficking. 
 
3.2. Sphingolipid analysis 
Sphingolipids have been traditionally analyzed by thin layer 
chromatography (TLC), which allows the separation and characterization of 
SLs by retention factors (Rfs) comparison with known standards [158]. 
More recently, SLs-specific ELISA immunoassays have been developed 
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[159]. However, this methodology allows to determine the SLs total content 
leaving unspecified the contribution of the saturated or unsaturated acyl 
chains.  
Furthermore, the wide dynamic range affecting sphingolipid composition in 
tissues and biological fluids requires sensitive technologies able to detect 
high and low abundant species; coupling a separative step with a precise 
detection of the chemical composition of molecules. The goal was achieved 
when mass spectrometry was introduced, and different ionization methods 
[160,161] and analyzers [162–164] were used successfully. Furthermore, 
the high homology among similar sphingolipids and the consequent 
mismatch [165] was overcome by coupling liquid chromatography [166], 
gas chromatography (GC) [167] and TLC or High-Performance Thin Layer 
Chromatography (HPTLC) [168–170] prior mass spectrometry analyses. 
LC-ESI MS/MS is nowadays the most utilized method [171,172], but other 
on-line hyphenated techniques have also been applied to sphingolipid 
research, such as LC-NMR [173], CE-MS [174] and TLC/HPTLC-MS [175–
178]. Despite cutting edge technologies, there are still some concerns 
about sphingolipid analysis connected to the profiling of SLs species in a 
single high-throughput analytical step. The last generation mass 
spectrometers have the possibility to get better inside into the 
sphingolipidome. However, the dynamic range is still far to be entirely 
resolved, and the complexity of the number and the structure of 
sphingolipids further complicate analyses.  
3.3. Sphingolipids and obesity 
The neologism “Globesity” perfectly defines the escalation of the pandemic 
of obesity, a complicated status in which the increase in nutrient intake, 
adipocyte dysfunction, insulin resistance, ectopic fat accumulation and 
inflammation act in synergy. Obese subjects are characterized by chronic 
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inflammatory status (pro-inflammatory cytokines) [179], availability of free 
fatty acids (FFA) [180] and oxidative stress [181]; all these features are 
connected with co-morbidities associated with obesity. A profound 
alteration of systemic metabolism induced by obesity and by obesity-related 
co-morbidities severely affect SLs homeostasis, generating unbalance 
targeting adipose tissue, liver, and skeletal muscle [182–184]. In 
physiological conditions, FFA are used as an energy source/storage, 
nevertheless, their pathological increment leads to apoptosis, insulin 
resistance, and to several alterations referred as “lipotoxicity” [185]. In 
obese subjects, sphingolipid metabolism is affected by increased bio-
availability of FFA, which induce increment of palmitoyl-CoA, thus 
increasing ceramide production via de novo pathway [186]. 
Studies on rodents show that saturated fatty acids (SFA) can stimulate the 
TLR-4, activating SMases converting SMs to Cers, contributing to 
increasing Cer levels [187,188]. Furthermore, the increment of pro-
inflammatory cytokines like IL-6 and TNF-α observed in obese subjects can 
play a central role in SLs modulation. In C57BL/6J mice the intraperitoneal 
administration of TNF-α induces upregulation of acid SMase (aSMase), 
neutral SMase (nSMase) and SPT suggesting that Cers level can be 
increased not only through de novo synthesis associated to higher 
availability of palmitoyl-CoA precursors but also to the indirect activity of 
TLR-4 and pro-inflammatory cytokines [189]. 
It is well known that obesity is connected to inflammatory response, 
however, the precise mechanisms that trigger this response are not 
completely clear, nonetheless activation of TLR-4 by lipopolysaccharides 
(LPS) [190], or by FFA [191], macrophage infiltration [192], adipose tissue 
expansion [191] and hypoxia [193] have been proposed as causative 
effects, leading to release of several pro-inflammatory cytokines, also 
known as adipokines [194,195]. The suggestion that saturated fatty acids 
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could be potential activators of TLR-4 [191] links ceramides increase to 
inflammation. William L. Holland [187] by using  in vivo and  in vitro models, 
induced TLR-4 activation, demonstrating that saturated fatty acid leads to 
ceramide-biosynthesis by activating TLR-4 and that increased Cers are 
required for TLR-4 dependent insulin resistance. TLR-4 is known to be 
responsible for initiating signals that activate NF-κB, JNK, and SOCS 
pathways [196,197], all factors involved in the regulation of inflammation. In 
1992 it was demonstrated by Dressler et al. [198] that the increment of 
TNF-α was able to reduce membrane sphingomyelin levels, increasing 
ceramide, suggesting that SMase was activated by TNF-α. This idea was 
further confirmed in 1994 by Schϋtze et al. [199], which showed an 
independent activation of aSMase and nSMase by TNF-α, resulting in an 
increased ceramide production and activation of NF-Kβ by aSmase. In 
2001 Teruel et al. [200] demonstrated increased levels of Cers in brown 
adipocytes treated with TNF-α and glucose and that the relocation of 
glucose transporter type 4 (GLUT-4) to the plasma membrane was inhibited 
by treating the same cell with a short-chain ceramide analog (C2-
ceramide). 
Furthermore, C2-Ceramide was indicated as activator of Protein 
phosphatase 2 (PP2A), leading to Protein Kinase B (AKT) 
dephosphorylation. Kolak et al. [201], confirmed that increased levels of 
ceramide and increased expression of SMases (SMPD1 and 2) 
characterized the subcutaneous adipose tissue of obese women with high 
levels of fat in the liver. Nevertheless, TNF-α increase was not statistically 
changed whereas other markers of inflammation (i.e., macrophage marker 
CD68, chemokines monocyte chemoattractant protein-1 and macrophage 
inflammatory protein-1alpha) were found at variance in a group of patients 
with high fat liver (NAFLD), supporting the hypothesis that an increased 
inflammatory status is associated with ceramide in obesity.  
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Despite increasing evidence supporting the role of ceramides in obesity-
induced metabolic disorders, a clear portrait for different ceramide sub-
species and their biological role still lacks; thus, the characterization of their 
actions in obesity and related-comorbidity is warranted, 
3.4. Ceramides and obesity 
Ceramide represents the central node of SLs, it is the keystone of 
sphingolipid molecules, and it is localized in the middle of the sphingolipid 
pathway. Even though it is not the most abundant SL in the human blood 
(accounting for 3% of the total SLs in serum) [202], it is the most studied. In 
the cell, Cers exert several actions [203], ranging from induction of 
apoptosis [204] and insulin resistance [205] to alteration of vascular tone 
[206]. 
The first study linking obesity, ceramides, and insulin resistance was 
conducted in 1990 by Turinsky J et al. [207] on Zucker diabetic fa/fa rats. In 
lean animals, 1,2-Diacylglycerol and ceramide levels were lower in muscle 
than in liver, whereas in Zucker diabetic fa/fa rats, both liver and muscle 
ceramide levels were high, suggesting a connection between ceramide and 
insulin resistance. 
In vivo, high fat diet (HFD) or  in vitro FFA administrations have been widely 
adopted as tools to stimulate weight gain on animal and cell models to 
mimic fat accumulation that precedes obesity [208–210]. Those type of 
induced-obesity allow to decipher the role of molecules without other 
confounding factors. Cell lines from murine myotubes [211] treated with 
radioactive palmitate, or human female myotubes supplemented with 
palmitate [212] show increased palmitate incorporation into ceramide and 
increased ceramide production, further supporting the idea that exogenous 
(dietary) oversupply of fatty acids, and specifically palmitate, is utilized to 
produce ceramide but also contribute to the increment of its levels. 
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Moreover, attention was focused on the acyl chain length of different 
ceramide species rather than total Cers, associating specific acyl chain 
activities to chain length. Murine models, fed with HFD or treated with 
palmitate, have shown increased ceramide C16:0 and C18:0 levels 
independently from tissue or cell type [213–220]. However, discrepancies 
after HFD treatment were noticed in the amount of some long-chain Cers in 
metabolic tissues as liver, skeletal muscle and adipose tissue (Table 1). 
Nevertheless, quantitative results were contradictory, Cer C24:0 has been 
shown to decrease in liver [213,216] and increase [214], as well as C24:1, 
that was decreased in [216], but increased in [214,215,221]. C24:1 gave 
conflicting results also in skeletal muscle, resulting decreased in [222] but 
increased in [214]. Conversely, Cer C22:0 decreased in adipose tissue 
according to [223] but increased in [216]. Total Cers increased in a study 
from Lyn-Cook et al. [224], which also demonstrated that HFD increased 
the expression of ceramide synthase, SPT and SMase in the liver. 
Ceramide was measured by dot blot in the liver and by ELISA in serum and 
resulted increased in HFD fed rats compared to LFD fed animals [225]. 
Ussher et al. [226], determined Cers levels derivatizing the molecule to an 
o-Phthalaldehyde to generate a fluorescent compound that was separated 
by HPLC and quantified by fluorescence spectrometry. In gastrocnemius, 
ceramide was doubled in HFD fed animals, whereas hepatic ceramide 
levels were unaffected, in countertrend to Lyn-Cook data [224], that utilized 
the same quantification method on the same animal model. Other 
discrepancies were described for sphingosine, in one work by LC-MS, 
sphingosine increased [227,228], whereas, with fluorescence, no changes 
were detected [229] (Table 1). 
These results suggest that, before considering data as absolute, a careful 
evaluation of the efficiency of the methods adopted for quantitation have to 
be carefully considered. 
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Levels of ceramide, insulin resistance and glucose intolerance observed in 
HFD mice were completely reversed by treatment with myriocin (a de novo 
Cer biosynthesis inhibitor). Utilizing C57BL/6J mice, Boini KM et al. [230] 
discovered a significant increase in plasma ceramide levels in mice on an 
HFD and that the treatment with amitriptyline (an inhibitor of both SMases 
and CDases) was able to reduce plasma ceramide levels. By studying non-
alcoholic fatty liver disease on Long-Evan rats, Longato et al. [225] 
confirmed previous results, highlighting the detrimental role of HFD. In 
particular, HFD compared to low-fat diet (LFD) led to NALFD, peripheral 
insulin resistance, increased expression of pro-ceramides gene in liver and 
increased levels of serum ceramides. Kurek et al. [229], confirmed in Wistar 
rats that HFD by itself was able to determine NAFLD and induce insulin 
resistance; nevertheless, treatment with myriocin was able to reduce DAG, 
TAG and Cer levels in liver, leading to a reduction on NAFLD severity.  
The use of leptin-deficient ob/ob mice models partially confirmed these 
data, even if Samad et al. [189] detected a decrement of total Cers in 
adipose tissue, other authors investigating the same HFD fed animals 
indicated increase of most of acyl chain Cers in the same tissue 
[216,217,223] (Table 2). In human subjects, Haus JM et al. [231] found that 
obese T2DM patients had higher plasma concentration of total, C18:0, 
C20:0, C24:0 and C24:1 Cer compared to control and the same Cer chains 
were inversely correlated with insulin sensitivity. However, the same Cer 
C18:0, C20:0 and C24:1 were not detected as changed in serum of obese 
subjects by [232] (Table 3). Concerning the quantitative assessment of 
different acyl chains Cers, several discrepant data characterized both 
animal models and human subjects, thus data have to be considered 
cautiously. 
Turpin SM et al. [223] demonstrated that CerS6 mRNA expression and Cer 
C14:0, C16:0, C16:1, C18:0, C18:1 and C22:1 were elevated in obese 
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adipose tissue from mice and that an increase in CerS6 positively 
correlated with insulin resistance in humans. These data were further 
confirmed by CerS6 deficient mice, which were protected from HFD and 
showed reduced obesity, glucose intolerance and low levels of Cer C16:0. 
Recently, Raichur S et al. [233] demonstrated using antisense 
oligonucleotide (ASO) in leptin-deficient ob/ob and HFD mice models that 
CerS6 ASO treatment determined a reduction in the CerS6 expression in 
liver and decrement of subcutaneous and visceral fat. Furthermore, this 
treatment induced a reduction of C16:0 ceramides plasma levels, resulting 
in improved glucose tolerance and insulin sensitivity, confirming the strict 
correlation between ceramide, obesity, and insulin resistance again. A 
recent study by Turpin SM et al. [234] revealed increased levels of C18:0 
ceramide and Cers1 overexpression in skeletal muscle of HFD fed mice, 
while in mice lacking Cers1, a reduction in levels of Cer18:0 is observed, 
and it is accompanied by the improvement of glucose homeostasis. 
However, the muscle-specific deficiency of CerS5/6 failed to protect mice 
from obesity-induced insulin resistance [234], highlighting the relationship 
among acyl chain length and isoforms of Cers (1-6) enzymes.  
Table 1. Discrepancies in sphingolipid’s species alteration in HFD animal models. 
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Table 2. Discrepancies of sphingolipid species alteration between ob/ob mice and HFD fed 
animals. 
 
Table 3. Discrepancies of sphingolipid species between plasma and serum in obese human 
subjects. 
 
3.5. Dihydroceramides and obesity 
Dhcers were considered for long time inactive precursors of ceramides, 
generated during the de novo synthesis, since the short-chain (C2-C6) 
ceramides, and not their saturated counterpart were able to stop cell 
proliferation and to induce apoptosis [235–237]. Only in 2006, a bioactive 
role for dhCers was first acknowledged by Zheng et al., during a lipidomic 
screening of cultured cells treated with fenretinide, an anticancer drug 
supposed to induce cell death through ceramide-mediated action. After 
treatment, dhCers levels increased, whereas the expected increase of 
ceramide was not observed [238]. 
In 2013 Brozizick et al. [239] revealed that monkeys under a long period of 
HFD showed increased plasma levels of Cer and dhCer, exacerbated when 
animals developed diabetes. In 2013, Lopez et al. [240] discovered that, 
among dhCers, only C24:1 were increased in plasma of obese children and 
adolescent females with T2DM. Mamtani et al. [241] performing an analysis 
of the human lipidomic profile, discovered in Mexican Americans a peculiar 
association between plasma levels of dhCers 18:0, 20:0, 22:0 and 24:1 and 
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waist circumference. Bergman et al. [242] investigating the effects of 
exercise in relation to the sphingolipid metabolism in human subjects, 
linked dhCer and insulin resistance and found that total dhCer together with 
C16:0 ceramide and C18:0 sphingomyelin were higher in T2DM subjects 
and positively correlated with insulin resistance. More recently, a work by 
Wigger and colleagues [243] identified a specific group of sphingolipids that 
correlate with glucose intolerance and insulin secretion in mice. Notably, 
dhCer C22:0 could be used in humans as biomarkers of T2DM disease 
progression. Several studies described correlations among insulin and 
obesity, metabolic parameters and dhCers linking them to the development 
of metabolic disorders, although the pathophysiological mechanisms 
associated with these molecules are still unknown [244]. 
Most of the studies in the context of dhCer alterations rely on Des1, the 
enzyme that introduces the double bond in dhCers producing Cers. Mice 
Des1−/− resulted in an incomplete penetrance lethality phenotype 
characterized by increased levels of dhCer and decreased levels of Cer 
[245]. 
Another study [246] described the increment of arterial ceramide-induced 
by HFD in Des1+/+ but not in Des1+/− mice, although Des1+/− HFD 
animals developed a severe increase of fat mass, decreased lean mass 
and impaired glucose tolerance than Des1+/+. Nevertheless, Des1+/- mice 
from [246], develop a more severe metabolic alteration compared to 
Des1+/- mice, described by Holland and colleagues [245]. Both papers 
pointed out that the causative role for the metabolic alterations leading to 
insulin resistance and vascular dysfunction has to be ascribed to the rate of 
conversion of dhCer to Cer more than dhCer itself. 
Conversely, Barbarroja et al. [247], indicated that, both in vivo and in vitro 
Des1 reduction, impairs adipogenesis and lipogenesis, and that adipocyte 
treatment with dhCers resulted in metabolic dysregulation. 
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It can be concluded that Des1 is a crucial enzyme in sphingolipid 
generation, and its activation or impairment is crucial for sphingolipids 
homeostasis. Nevertheless, it is still not completely clear if its role in 
metabolic alterations is due to its increment or due to the decrement of its 
product. Further investigation will be required to precisely define 
pathophysiological mechanisms regulated by this enzyme, which is pivotal 
in obesity. 
3.6. Sphingomyelins and obesity 
Sphingomyelin is one of the most abundant sphingolipids in body fluids and 
tissues, accounting for 87% of total plasma sphingolipids [202]. 
Correlations have been found among high levels of SMs and cholesterol, 
coronary artery disease in humans and HFD and insulin sensitivity in mice 
[216,248,249]. Conversely, in the adipose tissue of ob/ob mice, reduced 
levels of SMs and increased SMases (both neutral and acidic) mRNA 
expression were observed, and the more significant decrease was 
observed in long-chain SMs (20:0, 20:1, 22:1, 24:0, 24:1) (Table 2). 
Interestingly, serum levels of SMs increased in ob/ob mice, suggesting an 
intriguing SLs flux from tissue to body fluids [189]. Norris and colleagues, 
utilizing a C57BL/6J mice fed with HFD for ten week, found that mice fed 
with HFD and supplemented with SMs displayed reduced hepatic steatosis, 
lower cholesterol, lower liver TG accumulation and tissue macrophage 
infiltration, suggesting that SMs dietary supplementation could ameliorate 
metabolic complications induced by HFD [250]. The question is if the 
exogenous sphingomyelin acts differently compared to the endogenous 
one, or if these differences are related to adopted quantitative 
methodologies (enzymatic methods and TLC) is still opened.  
Localization of SMs plays a vital role in overweight and obesity. Hints on 
this direction were provided by Mitsutake and colleagues investigating the 
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sphingomyelin synthase 2 (SMS2) KO mice [251]. These mice exhibited a 
reduced number of large and mature lipid droplets in the liver, caused by 
lack of SM and by the association of SMS2 with the fatty acid transporter 
CD36/FAT and caveolin 1. Also, SMS2 KO mice did not increase their body 
weight by HFD, suggesting SMS2 as a target to prevent high fat diet-
induced obesity and insulin resistance. 
Studies on human subjects by Hanamatsu et al demonstrated that, in 
obese, SMs saturated acyl chain (C18:0, 20:0, 22:0, and 24:0) were 
increased compared to control group and positively correlated with serum 
biochemical (TC, TG and LDL-C) and insulin resistance parameters 
(Homeostatic model assessment of insulin resistance (HOMA-IR), AST and 
ALT) [252]. 
Recent metabolomic studies identified correlations between 
lysophosphatidylcholine (LPC) (lysoPC C17:0, 18:1, and 18:2) and obesity, 
whereas sphingomyelins (C18:1) and dhCers were associated to pre-
diabetic insulin state [253]. 
Bagheri and colleagues, at variance, found a negative association between 
LPC and obesity (C18:1 and C18:2) in obese Iranian adults without any 
correlation among SMs and obesity [254]. 
Hellmuth et al. [255], on the other hand, by investigating metabolomics 
profiles and insulin resistance in European children, found that SMs C32:2 
was strongly associated with BMI z-score, whereas the association with 
HDL and body weight was absent. Recently, Im and colleagues [256] found 
that SM concentration correlated positively with cholesteryl esters and waist 
to hip ratio, and that sphingomyelin levels are higher in pre-diabetic men 
with abdominal obesity. 
The effects of SMs in obesity or the obesity-induced generation of SMs are 
slightly disregarded compared to Cers, even though their levels in obesity 
or HFD increased in serum [189], liver [215], adipose tissue [216] 
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erythrocyte and heart [257]. Altogether these studies suggest that 
sphingomyelin and its different acyl chains can play a causative effect in 
the onset and development of obesity. However, results are, to some 
extent, contradictory. To define the precise role of SMs in obesity will 
require a strict control of sampling, the use of defined standards and the 
identification of standardized analytical procedure to overcome the lack of 
reproducibility that in sphingolipid research remain a central node. 
3.7. S1P and obesity 
Sphingosine is produced by ceramide breakdown, and the sphingosine-1-
phosphate represents its phosphorylated counterpart. Both molecules are 
key signaling bioactive elements in liver [258], muscle [259], blood [260], 
and adipose tissue [261]. Despite their consistent signaling activities, 
studies investigating their role in obesity are limited compared to other SLs.  
Kowalsky and colleagues [262] investigated S1P plasma levels by a 
commercially available ELISA, indicating an increase of S1P in mice 
characterized by genetically and HFD induced obesity. The study was 
extended to humans identifying a positive correlation among S1P and BMI, 
total body fat percentage and HOMA-IR. Notably, S1P levels increased in 
mice after 12 h fasting, suggesting that the S1P pool is quickly modified 
and S1P can exert potentially positive effects contributing to 
recovery/surviving of pancreatic Β-cells during the compensatory 
hyperinsulinemia status in insulin-resistant and obese subjects.  
Revising the literature, studies on human subjects as well as on animal 
models provided different results even by using the same quantitative 
methodology. Majumdar et al. described no differences in S1P levels in 
obese adolescents [232], whereas Ito et al. [263] confirmed the S1P 
increase in obese in line with Kowalsky. 
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The S1P increment in mice was confirmed by Fayyaz [264], which identified 
increased levels of hepatic S1P in HFD fed New Zealand obese mice. An 
increase in S1P was also seen in primary culture of rat and human 
hepatocytes supplemented with palmitate. Furthermore, the S1P increment 
decreased insulin stimulation of the PI3K/AKT signaling through the 
sphingosine-1-phosphate receptor 2, proposing a negative regulatory effect 
of S1P on insulin signaling in hepatocytes. These observations were not 
confirmed by Kurek et al., who identified increased levels of Cers and SMs 
nor of S1P in the liver of male Wistar rats fed with an HFD, neither after 7-
day treatment with myriocin [217]. 
In a recent paper, the group of Kleuser [265] was able to clarify in-vivo the 
apparent discrepancy between the pro-survival effect of pancreatic β-cell 
suggested by Kowalsky and increased hepatocyte insulin resistance 
mediated by S1P. Analyzing New Zealand obese mice (that develops β-cell 
loss under HFD), they identified an increase in T2D prevalence, paralleled 
by increased levels of S1P in plasma. Mice treated with a specific 
sphingosine-1-phosphate receptor 2 antagonist (JTE-013) by counteracting 
the binding of S1P. This action induces disruption of insulin signaling and β-
cell dysfunction, suggesting that S1P can act on pancreatic β-cell by 
increasing its levels or by binding to different receptors; thus, it can both 
lead to a negative or positive outcome. 
In 2012, Moon et al. [266] identified on C57B/6J mice and 3T3-L1 cells the 
central role of the sphingosine-1-phosphate analog (FTY720) in the 
regulation of adipogenesis and lipolysis. This molecule was able to down-
regulate adipogenesis and enhance lipolysis, both  in vivo and  in vitro, 
opening a new avenue in the treatment of obesity. 
Interestingly, the same group [267] demonstrated that S1P was able to 
reduce TG accumulation and to inhibit differentiation in 3T3-L1 
preadipocytes, resulting in the downregulation of markers of adipogenic 
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differentiation like peroxisome proliferator activated receptor γ (PPAR γ), 
CCAAT/enhancer binding protein and adiponectin. Surprisingly, it has been 
reported that the action of S1P and FTY720 toward the SphK receptor 1 is 
different, it is based on the recycling of the ligand in the former and 
degradation in the latter [268]. 
A positive role for S1P in obesity was also observed by Silva et al. [269] 
that, in 2014, identified the S1P/sphingosine kinase receptor1 axis as a 
central node in energy homeostasis. S1P intracerebroventricular injection 
was able to reduce food intake, increasing rat energy expenditure, arising 
the questions of differences between exogenous and endogenous 
sphingolipids. 
Levels of S1P and sphingosine are finely tuned inside cells, tissue, and in 
body fluids and are regulated by sphingosine kinases 1-2 (SphK1-2) and 
sphingosine phosphatases [154]. The administration of exogenous 
palmitate to C2C12 myotubes was able to increase levels of S1P and 
activity of SphK1 [211]. Notably, this was not observed when myotubes 
were treated with oleate, suggesting that Sphk1 is activated in the presence 
of palmitate, only. In 2013, the same group was able to dissect the 
mechanism through which palmitate was able to induce SphK1 increase in 
muscle [270]. Sphk1 overexpression was linked to the interaction between 
peroxisome proliferator-activated receptor-α (PPAR-α) and SphK1 
promoter. However, it remains unclarified if SphK promoter induction was in 
response to direct PPAR-α interaction or due to PPAR-α downstream 
signaling. 
In 2018 Nagahashi et al. [271], investigating the link among obesity, 
inflammation and cancer, confirmed that in breast cancer patients and 
animal models the HFD alone was able to induce the axis 
SphK1/S1P/S1PR1 and to stimulate in obesity a cancer-associated pro-
inflammatory cytokines (IL-6 and TNF-α). Treatment with FTY720 was able 
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to reduce activation of the S1P axis and levels of cytokines, resulting in 
prolonged survival of HFD-administered tumor-bearing mice. 
Not only SphK1 but also SphK2 contribute to the action of S1P. Notably, 
SphK2 -/- mice are protected from diet-induced obesity and develop a lean 
phenotype and improved glucose tolerance [272] and are characterized by 
a two-fold increase of S1P in plasma suggesting that the inhibition of 
SphK2 contributes to the maintenance of high levels of S1P, potentially 
positive in the treatment of obesity. Through these studies, it can be 
hypothesized that the S1P increase follows two possible mechanisms: 
upregulation of SphK1, already seen in other animal models lacking SphK2 
[273], or inhibition of the SphK2 gene [274,275]. 
Collectively this data indicate that S1P is an essential player in obesity and 
obesity-related comorbidities, through its pleiotropic intracellular and 
extracellular activities target different pathways, even if its role remains so 
far unclear. The outcomes of S1P increment is at variance in human and 
animal models, being protective in obese subjects and detrimental in 
animal models leaving opened the question in obesity if animal models can 
recapitulate the human conditions. 
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4. AIM OF THE STUDY 
The World Health Organization defines obesity as abnormal or excessive 
deposition of fat that contribute to put your health at risk [276]. This 
frequent status is not due to food intake only, but other contributing factors 
like genetic background, inactivity and hypercaloric food intake [3–5] play a 
role.  
This condition is also associated with vitamin D deficiency involved in 
obesity-associated morbidities [6]. Two recent studies assessing serum 
proteomic alterations in obese Saudi Arabian Vit. D deficient subjects 
identified differentially expressed proteins related to Vit. D function, 
inflammation/immunity and lipid metabolism [277,278]. Along with Vit. D 
deficiency, a peculiar class of lipids called sphingolipids have been 
identified as contributors to the chronic low-grade inflammation status 
[10,11] observed in obese subjects and also in obesity-associated 
comorbidities [12–14]. Sphingolipids metabolism is profoundly 
interconnected with inflammation, the increase in pro-inflammatory 
cytokines (IL-6, TNF-a) observed in obese subjects, results in the activation 
of sphingomyelinases (SMases), both directly and via toll-like Receptor-4 
(TLR-4), [279] that hydrolyzes SMs to Cers. Furthermore, increased plasma 
free fatty acids levels of obese subjects, stimulate Cers de novo 
biosynthesis by providing increased substrate for serin-palmitoyl 
transferase (SPT) [280]. 
SLs levels are pretty well described in tissues, but a precise knowledge of 
their flux in biological fluids and their relative effect over different target 
tissues is still lacking. Recent data show that SLs travel in body fluids 
mainly in association with albumin, low-density lipoprotein-cholesterol (LDL-
C), very low-density lipoprotein cholesterol (VLDL-C) and high-density 
lipoprotein cholesterol (HDL-C) particles; and that the level of different SLs 
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associated to a particular lipoprotein correlate with obesity-related 
comorbidities as, the increased risk of developing non-alcoholic fatty liver 
disease (NAFLD) or the increase in cardiovascular risk [186,281]. 
This study approached the role of sphingolipids in obesity, assessing 
sphingolipids flux in biological fluids in the presence of Vit. D deficiency and 
dyslipidemia. The general aim of this study was to precisely characterize 
SLs profiles in two different population. The first, from Saudi Arabia, was 
defined by a high prevalence of obesity, Vit. D deficiency and dyslipidemia, 
while the latter, from the Andean region of Argentina, was characterized by 
a low prevalence of obesity but high levels of Vit D. deficiency and 
dyslipidemia. 
The aim of the first study was to analyze SLs profiles of normal-weight 
subjects in presence/absence of dyslipidemia to decipher the contribution 
of dyslipidemia on SLs profiles and furthermore to assess SLs profiles in 
Vit. D deficient dyslipidemic obese and lean subjects to identify SLs 
patterns not related to dyslipidemia, therefore potentially attributable to 
weight gain. The second study was aimed at profiling sphingolipids in 
groups characterized by different BMIs but similar Vit D. deficiency and 
dyslipidemic traits, in order to provide a molecular signature not only of 
obesity but also of possible different phenotype adaptation to high altitude 
hypoxia. 
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5. MATERIALS AND METHODS 
5.1. Participants and Sample Collection  
(Arabian subjects) 
Men and women adult Saudis were enrolled from the Vitamin D School 
Project Database of the Prince Mutaib Chair for Biomarkers of 
Osteoporosis, College of Science, King Saud University, Riyadh, Kingdom 
of Saudi Arabia [282]. The study was approved by the Ethics Committee of 
the College of Science, King Saud University in Riyadh, Saudi Arabia (Ref 
No. 15/0502/IRB). Enrolled subjects provided their full informed consent. All 
subjects were grouped according to the BMI into normal weight (BMI 
<25kg/m2) and obese (BMI ≥30kg/m2). Serum samples were collected from 
23 normolipidemic normal weight (NWNL) controls, 46 vitamin D deficient 
dyslipidemic (HDL-C <40 mg/dL; TG >200mg/dL) normal weight (NWDL) 
and from 60 vitamin D deficient obese (ODL) subjects, and stored at -80°C 
until use. Adult Saudis parameters for: age, gender, weight (Kg), height 
(Cm), BMI, total cholesterol (mg/dL), HDL-C (mg/dL), LDL-C (mg/dL) and 
Vitamin D (ng/mL) can be found in Table 4. BMI was calculated as weight 
(Kg) divided by height squared (m). TC, HDL–C, and TG were obtained 
using a chemical analyzer (Konelab, Espoo, Finland), while LDL-C levels 
were calculated using the Friedewald’s formula. Vit. D levels were obtained 
by electrochemiluminescence immunoassay on Roche Elecsys Cobas 
e411 analyzer (Roche Diagnostics, GmbH, Mannheim, Germany). 
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5.2. Participants and Sample Collection  
(Andean subjects) 
Fifty-nine children (age 5–13 years) from San Antonio de Los Cobres (3775 
m a.s.l.), who were previously enrolled [283], were classified as UW (<5th 
percentile), NW (5th to < 85th percentile), OW (85th to < 95th percentile), or 
O (≥95th percentile) on the basis of their body mass percentiles, 
accordingly to the US Centers for Disease Control and Prevention (CDC) 
norms [29]. Children’s anthropometry—age, gender, weight (kg) and height 
(cm)—are indicated in Table 6. TC (mg/dL), HDL-C (mg/dL), LDL-C 
(mg/dL), Vit. D, ng/mL), fasting glucose (Glycaemia, mg/dL), fasting insulin 
(Insulin, µU/mL), and triglycerides TG, mg/dL) were assessed, while BMI, 
TC/HDL-C ratio, and HOMA-IR were calculated as follows: BMI was 
calculated as weight (kg) divided by height squared (m); TC/HDL-C ratio 
was calculated as TC(mg/dL)/HDL-C(mg/dL); while HOMA-IR was 
calculated as Glycaemia (mg/dL) × Insulin/405. Blood samples were 
collected after 10-h fasting. Fasting glucose was measured by glucose 
oxidase, while serum lipids were assessed with Architect c 16000 
instrument (Toshiba, Kanagawa, Japan). Chemiluminescent was utilized for 
the detection of fasting insulin levels and serum Vitamin D (Abbott 
Laboratories, Chicago, IL, USA). 
The study was carried out following the rules of the Declaration of Helsinki 
and was approved by the Human Rights Committee of the Salta Health 
Ministry (project number: 4518; date of approval: 8 November 2010). Each 
caregiver and child gave written informed consent after an explanation of 
the study and before its initiation. 
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5.3.  Reagents and Chemicals 
Methanol, Propan-2-one, 1-butanol LC-MS grade water, 3,5-Di-tert-4-
butylhydroxytoluene (BHT), primuline yellow dye, and ammonium formate 
were from Sigma-Aldrich (Saint Louis, MO, USA). Ethanol and HPLC 
analytical grade chloroform were, respectively, from J.T. Baker (Center 
Valley, PA, USA) and Carlo Erba (Cornaredo, MI, Italy). Potassium 
hydroxide was from Merk Millipore (Burlington, Massachusetts, USA). 
Acetic and formic acid were from Fluka-Analytical (Honeywell, Morris 
Plains, NJ, USA). N-lignoceroyl-D-erythro-sphingosine (Cer C24:0) 1,2-
Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC), Cardiolipin (CL), 1,2-
Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine (DPPE), D-glucosyl-ß-1,1'-
N-stearoyl-D-erythro-sphingosine-d5 (GlcCer), N-lauroyl-D-erythro-
sphingosine , N-lauroyl-D-erythro-sphinganine, N-lauroyl-D-erythro-
sphingosylphosphorylcholine N-lauroyl-D-erythro-
sphinganylphosphorylcholine, D-glucosyl-ß-1,1'-N-lauroyl-D-erythro-
sphingosine, D-lactosyl-ß-1,1' N-lauroyl-D-erythro-sphingosine and C17 d-
erythro-dihydrosphingosine-1-phosphate lipids standards. Sphinganine 
(d17:0), sphinganine-1-phosphate (d17:0), C12 Ceramide, Sphingomyelin 
(d18:1/12:0), Glucosyl (β) C12 Ceramide, d-31 phosphatidylcholine, Lyso-
phosphatidylcholine (C17:0), d-31 phosphatidylethanolamine, d5-
diglyceride (17:0/17:0), d5-triglyceride (17:0/17:0/17:0) and cholesteryl 
ester (17:0) were from were from Avanti Polar Lipids (Alabaster, AL, USA). 
Sphingolipids standard mixture containing Sphingomyelin (SM) and 
Sulfatides (SLF) was from Matreya LLC (Pleasant Gap, PA, USA). 
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5.4. HPTLC-profiling (Arabian subjects) 
5.4.1. HPTLC lipid Extraction 
Serum samples from 129 adult subjects were analyzed. Briefly, serum 
aliquots of 100µL were mixed with 1 ml of methanol/butanol 1:1 (v/v) 
containing ammonium formate 5mM. Mixtures were vortexed for 10 
seconds, sonicated for 1 hour in a sonic water bath (20°C) and centrifuged 
for 10 minutes at 16000g (20°C). Liquid phases were collected and 
transferred in borosilicate glass vials with Teflon-lined caps (VWR, Radnor, 
PA) and, after nitrogen-flux drying, re-suspended in 150μL of 
chloroform/methanol 2:1 (v/v) containing BHT 0.01% (w/v) and stored at -
20°C. 
5.4.2. HPTLC-Primuline profiling 
Aluminium backed HPTLC silica plates 200x100mm (Merck, Billerica, 
Massachusetts), were washed in chloroform/methanol 1:1 (v/v), and dried 
at 120°C for 20 minutes. A volume corresponding to 100µg of total protein 
was loaded in duplicate on HPTLC plates using Linomat 5 semiautomatic 
TLC spotter (CAMAG, Switzerland) (lane width: 6 mm, dosage speed: 
150nL/s). Two different standard mixtures were loaded on HPTLC plates’ 
lateral edges. The first mixture consisted of SM, SLF, GlcCer, and C24:0 
standards; the second one was made of CL, DPPE, and DPPC. 
Loaded HPTLC plates were developed in a solution of 
chloroform/methanol/water 55:20:3 (v/v/v), using Camag Automatic 
Developing Chamber 2 (CAMAG, Switzerland). Developed plates were 
sprayed with a solution of primuline yellow dye, 5mg/100ml in propan-2-
one/water 80:20 (v/v). Images were acquired using Ettan DIGE Imager (GE 
Healthcare, Chicago, IL, USA). Imager settings were: pixel size 100µm, 
excitation filter 480/30, emission filter 592/25. Acquired images were 
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analyzed using ImageQuant software v.8.1 (GE Healthcare, Chicago, IL, 
USA). 
5.5. UPLC-MS/MS (Arabian and Andean subjects) 
5.5.1. UPLC-MS Sphingolipid Extraction 
Sphingolipids were extracted from sera, following minor modification, 
according to a previous study [284]. 0.1 mL of serum was mixed with 0.1 
mL of ultrapure water and 1.5 mL of methanol/chloroform 2:1 (0.01% BHT), 
fortified with internal standards 200 pmol: Sphinganine (d17:0), 
sphinganine-1-phosphate (d17:0), C12 Ceramide (d18:1/12:0), C12 
Sphingomyelin (d18:1/12:0), and Glucosyl (β) C12 Ceramide. After a brief 
sonication, samples were heated at 48 °C overnight. 0.15 mL of KOH 1 M 
in methanol was added, and after 2-h incubation at 37 °C, the solution was 
neutralized with 0.15 mL of acetic acid 1 M and dried. After resuspension in 
0.5 mL of methanol, solutions were transferred to a clean Eppendorf tube. 
Samples were dried again, resuspended in 0.15 mL of methanol, and 
centrifuged for 3 min at 10,000 g. Liquid phases were collected in UPLC 
glass vials and stored at −80 °C. 
5.5.2. UPLC-MS quantification 
For sphingolipid analysis of Saudi Arabian subjects, 72 sera were randomly 
sub-pooled into 24 pools (8sub-pool for NWNL, 8 for NWDL and 8 for 
ODL). The pooling was adopted as a method to reduce the variance among 
biological groups increasing the power to detect changes when few 
samples are available, and the variance is high [285,286]. 
The sphingolipid analyses of Andean subjects were conducted on 59 sera 
samples. 
Liquid chromatography-mass spectrometer configuration included a Waters 
Acquity UPLC system linked to a Waters LCT Premier Orthogonal 
Accelerated Time of Flight Mass Spectrometer (Waters, Millford, MA, USA). 
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The instrument operated in positive or negative electrospray ionization 
mode. Full scans were obtained in a window, ranging from 50 to 1500 Da. 
Accuracy and reproducibility were maintained employing an independent 
reference spray via LockSpray. First, 10 µL of sphingolipid extract were 
injected and separated on an analytical column, kept at 30 °C, 100 mm × 
2.1 mm id, 1.7 µm C8 Acquity UPLC BEH (Waters), using the following 
linear gradient: 0.0 min: 80% B; 3 min: 90% B; 6 min: 90% B; 15 min: 99% 
B; 18 min: 99% B; 20 min: 80% B, at 0.3 mL/min flow rate. Phase B 
consisted of 1 mM ammonium formate in methanol, 0.05 mM formic acid, 
while phase A was 2 mM ammonium formate in H2O, with 0.05 mM formic 
acid. Sphingolipids quantification was carried out using the ion 
chromatogram obtained for each compound using 50 mDa windows. The 
linear dynamic range was determined by injection of standard mixtures. 
Identification of compounds was based on the accurate mass 
measurement, with an error <5 ppm and its retention time, compared to that 
of a standard (± 2%). Mass spectra were analyzed by MassLynx™ 4.1 
Software (Waters, Millford, MA, USA), and lipids were annotated as lipid 
subclasses as follows (sphingosine backbone/number of carbon atoms of 
the fatty acid: number of unsaturation of the fatty acid). A paragraph 
explaining which sphingolipid species were identified and quantified and the 
single lipid species added to obtain total class levels can be found in 
supplementary file 1. 
5.5.3. MRM Analysis 
S1P was quantified in 59 specimens from Andean subjects and on 24 pool 
from Saudi Arabian subjects using a Xevo TQ-MS mass spectrometer 
(Waters, Millford, MA, USA). Briefly, 10 µl of sphingolipid extracts were 
injected and separated on an analytical column, kept at 30 °C, 100 mm × 
2.1 mm id, 1.7 µm C8 Acquity UPLC BEH (Waters). The following gradient 
was used: 0.0 min: 80% B; 3 min: 90% B; 6 min: 90% B; 9 min: 99% B; 12 
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min: 99% B; 14 min: 80% B, at 0.3 mL/min flow rate. Phase B consisted of 
1 mM ammonium formate in methanol, 0.05 mM formic acid, while phase A 
was 2 mM ammonium formate in H2O, with 0.05 mM formic acid. An 
electrospray interface operating in positive ion mode was employed to 
obtain MS/MS spectra by acquiring MRM transitions of: C17 sphinganine-1-
phosphate, 368.4–252.4, collision energy 18 eV; Sph 300.4-264.4 Da, 
collision energy 16eV; dhS1P, 382.4- 284.4, collision energy 16 eV and 
S1P, 380.4–264.4 Da, collision energy 16 eV. Mass spectra were analyzed 
by MassLynx™ 4.1 Software. 
5.6. Statistical Analysis 
5.6.1. Arabian subjects 
Participants were grouped according to sex, obesity, and dyslipidemia 
status, and their characteristics were described using median and 
interquartile range, if continuous, and percentages, if categorical. 
Comparison of biochemical parameters like age, weight, height, BMI, TC, 
HDL-C, LDL-C, Vitamin D, and TG were investigated between groups using 
One way ANOVA with Bonferroni’s correction if data were normally 
distributed, otherwise the Kruskal-Wallis’ with Dunn’s correction was 
adopted. Circulating levels of Cers and SMs were transformed as logarithm 
and were compared by sex, weight group and dyslipidemia status using a 
generalized linear model (GLM) adjusted for BMI and age. Retro 
transformed least-square means from the GLM models were reported along 
with their standard errors, and comparisons were performed using the 
Tukey adjustment to control for inequalities of group size [287]. All 
statistical analyses were performed using the SAS software version 9.4, 
SigmaPlot software version 12.0, and Prism software version 7.0. 
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5.6.2. Andean subjects 
Participants were grouped according to their BMI percentiles, and their 
characteristics were described using median and interquartile range (if 
continuous) or counts and percentages (if categorical). Comparison 
biochemical parameters like age, weight, height, BMI, TC, HDL-C, CT/HDL, 
LDL-C, Vitamin D, glycaemia, HOMA-IR, insulin, and TG were investigated 
between groups using One way ANOVA with Bonferroni’s correction if data 
were normally distributed, otherwise the Kruskal-Wallis’ with Dunn’s 
correction was adopted. Correlation tables for sphingolipids and 
biochemical parameters were obtained using Pearson’s or Spearman’s 
correlation, when data were parametrically or not distributed, respectively. 
Differences in Cers, dhCers, SMs, dhSMs, HexCers, diHexCers, and S1P 
from LC-MS and LC-MS/MS quantitative data were assessed among 
groups. Statistical analyses were performed using SigmaPlot software 
version 12.0 and Prism software version 7.0. 
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6. RESULTS AND DISCUSSION 
6.1. Arabian Subjects 
6.1.1. Biochemical and anthropometric results 
Obesity and overweight prevalence in Saudi Arabia is increasing at an 
alarming rate. The last report from the WHO indicates that 44% of women 
and 28% of men are obese but also, that 71% of women and 66% of men 
are overweight [288], these data are confirmed by [289] and [290]. 
Furthermore, dyslipidemia represents also a significant health problem 
independently from BMI. A study by Al-Nozha MM and colleagues in a 
cohort of 16,819 patients identified hypercholesterolemia in 54% and 
hypertriglyceridemia in 40.3% of adult subjects, independently from their 
urban/rural origin [291]. These data were further confirmed by a more 
recent work by Hamam [292] that found an overall prevalence of 
dyslipidemia ( around 60% ) in a smaller group of University students and 
by Al-Kaabba et al. [293] that identified a prevalence of 44% for 
hypertriglyceridemia in a cohort of 4490 subjects [293]. Surprisingly, 
Vitamin D deficiency is another health concern, with reports indicating a 
prevalence of over 60% in the general population [294] and around 80% 
considering age and BMI [295]. Anthropometrical and biochemical data 
from 129 subjects enrolled in this study are summarized in Table 4. NWDL 
subjects were characterized by mean levels of LDL-C and TG classified as 
borderline or high, ODL subjects showed high levels of TG and slightly 
lower LDL-C levels compared to NWDL [296]. Conversely, NWNL subjects 
were characterized by acceptable mean levels of LDL-C and TG. 
Regarding HDL-C, NWNL subjects showed ideal levels, while ODL and 
NWDL showed levels lower than 40 mg/dL [297]. TC levels were borderline 
for both ODL and NWDL [297]. Levels of vitamin D, assessed in NWDL and 
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ODL groups, were low, being lower than the recommended level of 
30ng/mL [298], whereas NWNL subjects had normal levels of vitamin D.  
Table 4. Saudi Arabian subjects assessment of anthropometrical and biochemical 
parameters. Data are described by median and interquartile range (if continuous) or counts 
and percentages (if categorical).  
 
The prevalence of obesity, Vit. D deficiency and dyslipidemia in subjects 
enrolled in this study was 46%, 82%, and 82%, respectively. Therefore the 
analyzed groups show a prevalence consistent with Saudi Arabian general 
population for obesity and Vit. D deficiency. Conversely, the investigated 
subjects showed a higher rate of dyslipidemia (82% vs. 60% in Saudi 
Arabia) compared to Saudi Arabian general population. This study was 
focused on blood sphingolipids profiling to identify putative biomarkers to 
be used in clinical practice to reduce the risk of developing obesity-
associated morbidities. 
Differences between groups obtained from comparison of anthropometry 
and biochemical parameters are summarized in Table 5, while p-value from 
ANOVA one-way can be found in supplementary table 1.  
NWNL, NWDL and O group were homogeneous for age distribution, having 
a median between 39 and 45 years. The weight showed no statistically 
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significant differences between NWNL and NWDL, whereas ODL had 
higher BMI compared to NWNL and NWDL groups (p-value< 0.001 in both 
comparisons). 
NWLN group had a higher mean height than NWDL and ODL groups (p-
value< 0.001 in both comparisons). No difference was observed between 
NWNL and NWDL in BMI values, while both groups were statistically 
significantly different from ODL (p-value< 0.001 in both comparisons). Total 
cholesterol was higher in ODL and NWDL compared to NWNL (p-value< 
0.01 and p-value< 0.001 respectively). Furthermore, HDL-C levels were 
statistically significantly higher in NWNL than in ODL and NWDL (p-value< 
0.001 in both comparisons). NWDL showed high levels of LDL-C, higher 
than NWNL and ODL (p-value 0.001 in both comparisons), whereas ODL 
showed higher levels of LDL-C compared to NWNL (p-value< 0.01). TG 
levels were high in NWDL and ODL compared to NWNL (p-value< 0.001 in 
both comparisons) 
Table 5. Anthropometry and biochemical parameters comparison between different 
BMI/lipidic profile groups. One-way ANOVA with Bonferroni’s correction was employed if 
data were normally distributed, otherwise Kruskal-Wallis’ with Dunn’s correction was 
adopted. (*p-value < 0.05, **p-value < 0.01, ***p-value < 0.001). 
 
Results from anthropometrical and biochemical comparison among 
BMI/lipemia pointed out differences in weight and lipid composition, 
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clustering subjects in three different groups. Specifically, NWNL group was 
characterized by statistically significant differences in Vit. D, lipid profile and 
BMI compared to ODL. Conversely, NWDL and ODL were characterized by 
similar Vit. D deficiency and lipid composition, being divided only by their 
BMIs. No other parameters, except for height, were found to be at variance 
between groups, resulting in the absence of confounding 
biochemical/anthropometrical factors that could influence this investigation. 
These comparisons demonstrate that the three groups can be effectively 
clustered and that the comparison with their sphingolipidic profiles can be 
possible. 
6.1.2. Variations in sphingolipid profiles 
Circulating ceramide and sphingomyelin levels, from normolipidemic 
normal-weight individuals, were compared to dyslipidemic, vitamin D 
deficient, normal-weight or obese subjects, in order to identify variation in 
sphingolipid profiles.  
HPTLC-primuline profiling was the first technique of choice to semi-quantify 
SMs and Cers levels in our samples. Sphingolipid, obtained from 23 NWNL 
(15 men and 8 women) control subjects, 46 NWDL (23 men and 23 
women) and 60 ODL (25 men and 35 women) were extracted from sera, 
and the sphingolipid species were separated by HPTLC. After primuline 
staining, HPTLC-densitometry and FDIC (fluorescence detection by 
intensity changes) emission, detected SLs bands generating SLs profiles 
(supplementary figure 1). 
HPTLC-primuline profiling revealed six different bands in the HPTLC plate, 
but only bands corresponding to Cers and SMs could be identified by Rf 
comparison with standards. Both ceramides and SMs showed a clear 
separation in two distinct bands over the HPTLC plate. Bands showing 
Rf=0.176, Rf=0.152, Rf=0.923 and Rf=0.858, were attributed to SMs (C20-
C24), SMs (C14-C18), Cers (C20-C24) and Cers (C14-C18). 
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Results for Cers and SMs from HPTLC/primuline profiles comparisons and 
LC-MS data can be found in Figure 2.  
The LC-MS analysis was performed to precisely quantify variation over 
different acyl chain. The analysis was conducted on 8 sub-pools per group. 
The primuline profiling indicated a Cer C14-C18 decrease in NWNL 
compared to NWDL and ODL (p-value< 0.001 in both comparisons) (Figure 
2 A). Conversely, “short-chain” SMs (C14-18) were higher in NWNL subject 
compared to NWDL and ODL groups (p-value<0.001 in both comparisons) 
(Figure 2 C). Non-statistically significant results from Cers (C20-C24) and 
SMs (C20-C24) are reported in Supplementary figure 2. Long-chain SMs 
and cers from HPTLC-Primuline profiling did not provide significant results; 
nevertheless, the statistically significant trend identified for short chains 
(C14-18) was confirmed for long chains (C20-24), both SMs and cers 
(supplementary Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
Figure 2. A: HPTLC/primuline profiling of Cers C14-C18 in sera of NWNL (n=23), NWDL 
(n=46) and ODL (n=60) subjects. B: LC-MS analysis of total Cers and dhCers in sub-pooled 
sera from NWNL, NWDL and ODL subjects. C: HPTLC/densitometry profiling of SMs C14-
C18 in sera of NWNL (n=23), NWDL (n=46) and ODL (n=60) subjects. D: LC-MS analysis of 
total SMs and dhSMs in sub-pooled sera from NWNL, NWDL and ODL subjects. Tukey’s 
correction was employed after one-way ANOVA statistical analysis. Data are expressed in 
log scale and reported as mean ± SD. (*p-value < 0.05, **p-value < 0.01, ***p-value < 
0.001). 
 
LC-MS data confirmed variation highlighted by primuline profiling, in 
particular, total levels of Ceramide were found to be increased in NWDL 
and ODL subjects compared to NWNL (Figure 2B) and furthermore specific 
acyl chain C16:0, C20:0, C22:0, C22:1, C24:0, C24:1, and C24:2 were also 
found increased in the same comparison by LC-MS (supplementary figure 
3A and B). The analysis of sphingolipid profiles using two different 
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techniques allowed us to validate our results, being the adopted technique 
independent. HPTLC primuline profiling and LC-MS provided similar results 
for cers SMs and dhSMs. It should be noted that HPTLC-primuline profiling 
is a semi-quantitative method, while LC-MS is a precise quantification tool, 
so the latter is commonly preferred for quantifying sphingolipids [171,172]. 
Nevertheless, the results presented here show high levels of similarity 
between the two techniques, suggesting that the inexpensive HPTLC-
primuline profiling method could be adopted routinely for profiling and semi-
quantify sphingolipids in sera. NWDL and ODL comparison was otherwise 
characterized by the decrease of Cer C20:0, C24:1 and C24:2 in the ODL 
group. Total dhCers were found to be increased in the NWDL group only 
compared to NWNL, and a precise quantification of the acyl chain revealed 
that dhCer C16:0, C18:0, C20:0 and C22:0 had the same statistically 
significant trend. Moreover, acyl chain C18:0, C20:0 and C22:0 of dhCer 
were also found to be increased in ODL compared to NWNL 
(supplementary figure 3 C and D). 
Regarding Sphingomyelins, the trend compared to Cers was reversed. 
NWNL showed higher levels of SMs (C14-18) (Figure 2 C) compared to 
NWDL and ODL (p-value< 0.001 in both comparisons) and also total 
dhSMs were decreased in NWDL and ODL (Figure 2 D). More specifically, 
SMs acyl chains C16:0, C16:1, C18:0, C18:1, C20:1, C22:1 
(Supplementary figure 3 E and F) and dhSMs C14:0 and 16:0 
(Supplementary figure 3 G and H) were decreased in NWDL and ODL 
groups. 
The increase in cers and the decrease in SMs observed in ODL subjects 
could be the result of de novo SLs synthesis activation and of 
sphingomyelinase pathway. Ceramide generation, during HFD-induced 
obesity, is stimulated by the continuous and excessive supply of FFA from 
diet and adipose tissue, providing substrate for SPT and cerS(1-6) 
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[211,299], resulting in increased levels of plasmatic cers during obesity. 
The increased dhCer levels similar to Cers, in ODL subjects compared to 
NWNL further confirms the idea that de novo synthesis was altered in the 
obese group. 
In animal models, HFD administration stimulates the expression and the 
activity of both aSMase and nSMAse [215,225], while the pharmacological 
inhibition of aSMase by amitriptyline reduces HFD-stimulated ceramide 
release in blood [230], suggesting activation of the sphingomyelinase 
pathway during HFD-induced obesity. 
Regarding specific acyl chains influenced by obesity, we found peculiar 
chains of Cers, namely Cers C20:0 and C24:2 decreased in obese men 
compared to NWDL men, while cer C24:1 was decreased in ODL women 
compared to NWDL women (Supplementary Figure 3 A and B). Other 
chains were directly influenced by obesity in ODL men like dhSM C18:0, 
which was found increased compared to NWDL men (Supplementary 
Figure 3 G). In ODL women SM C16:0 was increased compared to NWDL 
women (Supplementary Figure 3 F). The fact that specific acyl chains of 
Cers were found at variance in obesity, rather than the total Cers, highlights 
the role of different Cer synthase isoforms in the regulation of SLs 
production during obesity. 
Little is known regarding SLs behavior during dyslipidemia and Vit. D 
deficiency. In plasma, sphingolipids, thanks to their hydrophilicity, circulate, 
bound to albumin and lipoproteins [186]. Particularly, cers are present and 
equally distributed in HDL-C, LDL-C and VLDL-C [202], while SMs travels 
for the 70% on LDL/VLDL-C and the 30% in HDL-C [202]. Interestingly, 
NWDL showed higher levels of total cers, dhCers and lower levels of SMs 
and dhSMs, compared to NWNL. Previous studies compared sphingolipids 
abundance in the obese group and lean healthy [231,262,300] or lean 
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normoglycemic [232] controls, without taking into account dyslipidemia as a 
confounding parameter.  
The increase of Cers and the decrease if SMs in obese subjects are well 
documented and the pathomechanisms almost known [301,302]. Our work 
confirms these data in obese subjects and expands the knowledge on 
sphingolipid profiling, suggesting that NWDL subjects, presenting Vit. D 
deficiency and dyslipidemia independently from obesity develop a 
sphingolipid plasma profile that is profoundly influenced by lipemia with 
dysregulated LDL-C, HDL-C and TG.  
It is possible to speculate that normal-weight subjects, presenting Vit. D 
deficiency and dyslipidemia, develop altered plasma SLs profiles because 
of the differential “transport” capacity of lipoprotein in their plasma, while 
the alterations observed during obesity are related to changes in SLs 
biosynthesis (e.g., de novo biosynthesis and sphingomyelinase pathway). 
6.1.3. Sphingolipid profiles and sex-related variations  
The study of obesity have to consider differences characterizing men and 
women, resulting not only in different phenotypes but also in a different risk 
for obesity-associated co-morbidities. Sexual dimorphism in body fat 
composition and distribution is not visible at infancy, starts at puberty and 
become present in adulthood [303]. These differences are so clear that 
results in the identification of different body shapes associated to gender, 
producing an android shape in men, characterized by accumulation of body 
mass above the waist [304], and a gynoid shape in women associated to a 
higher percentage of body mass below the waist [305]. In this context, 
women tend to accumulate more adipose tissue in the gluteofemoral area, 
whereas men develop mainly abdominal adipose tissue. Sex does not only 
influence adipose tissue distribution but also its localization; a predominant 
deposition of subcutaneous fat characterizes women while in men, visceral 
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fat is preferred [306]. Visceral adipose tissue and subcutaneous 
accumulation also differ for the type of adipocyte (which can present 
hyperplasia/hypertrophy) [307]. While in the subcutaneous fat, the 
hyperplasia is preferred, resulting in a more vascularized, more insulin-
sensitive and less inflamed tissue, visceral depots usually develop 
hypertrophic adipocytes; less vascularized, less effective in TG storage and 
prone to release inflammatory cytokines [308].  
The adipose tissue expansion, type, and localization are central modulators 
in the development of different metabolic risk between men and women. 
Subcutaneous adipose tissue is correlated to some extent to a metabolic 
protection from metabolic syndrome, insulin resistance and CVD, while 
visceral depots are associated with an increased risk of developing CVD 
and obesity-related co-morbidities [309]. 
From primuline profiling of “long chain” Cers and SMs, a trend, suggesting 
gender-specific differences was seen (Supplementary figure 2). 
To understand the impact of sex-related alteration, a direct comparison of 
the sphingolipid pattern for NWNL, NWDL, and ODL men and women was 
undertaken. NWNL men showed higher levels of cers C20:0, C24:1, C24:2 
(figure 3 A) and of total SMs, C18:0, C20:0, C22:1, and C24:1 (Figure 3B) 
when compared to NWNL women. Furthermore, NWNL women showed 
higher C18:0 diHexCer when compared to NWNL men (figure 3 F). On the 
contrary, in the NWDL group, women were characterized by higher SMs 
C22:0 when compared to men (Figure 3C). In the ODL comparison, men 
showed lower SMs C14:1 (Figure 3 D), higher dhSMs C18:0 (Figure 3 E) 
when compared to women and also lower total HexCer and C16:0 HexCer 
when compared to women (Figure 3 G) 
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Figure 3. UPLC-MS analysis of sex-related glyco/sphingolipid alteration in sub-pooled sera 
samples from NWNL men and women (A, B and F), NWDL men and women (C) and ODL 
men and women (D, E, and G).Unpaired t-test was employed. Data are expressed in log 
scale and reported as mean ± SD. (*p-value < 0.05, **p-value < 0.01, ***p-value < 0.001). 
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By this study, we were able to acknowledge the influence of gender, in 
modifying circulating SLs levels, independently from serum lipids and 
vitamin D status. 
Our data highlights the increase in Cer C20:0, C24:1 and C24:2 observed 
in normolipidemic normal-weight men compared to women; Weir et al. 
partially confirmed these data, in a cohort of 1431 Mexican Americans, 
where they found increased levels of ceramide C22:0, C24:0 and C24:1 in 
men compared to women [310], suggesting that an increase in cerS-2 
could be responsible for the increase in long-chain ceramides.  
In our study, total SMs, SM C18:0, C20:0, C22:1 and C24:1 increased in 
normolipidemic normal-weight men compared to women, while these data 
contrast with results published in other studies [311–313] that found higher 
levels of SMs in women’s. We found that in dyslipidemic normal-weight and 
obese women, the expected increase in SMs [312] was observed, and 
particularly SM C22:0 and C14:1 were increased compared to dyslipidemic 
normal-weight and obese men, respectively. 
The idea that gender could affect sphingolipid profiles led to further 
assessment of differences by analyzing different BMI groups, excluding the 
gender as a confounding factor.  
LC-MS data analysis from NWNL, NWDL and ODL men and women can be 
found in Figure 4. Men did not show particular alterations regarding 
sphingolipid, except for total diHexCers that were found to be statistically 
decreased in NWDL and ODL men compared to NW (Figure 4, panel A). 
On the contrary, women were found to be more subjected to variations in 
the sphingolipid profile, in fact, total HexCer was found increased in ODL 
compared to NWDL women (Figure 4, panel B) and more specifically, 
HexCer C16:0 was increased in NWNL and ODL compared to NWDL while 
diHexCer C24:1 was decreased in ODL and NWDL when compared to NW.  
63 
 
HexCer levels do not appear to have effects on insulin resistance in 
skeletal muscle; however, in adipocytes, glucosylceramide-synthase 
overexpression stimulates the suppression of insulin signaling [314]. The 
increase in plasma Hexcer levels of obese women compared to NWDL 
women can, therefore, be related to the overexpression of 
glucosylceramide-synthase in adipocytes and release of HexCers in the 
circulation. Moreover, hexosylceramide has been described as a possible 
inducer of plaque inflammation and instability [315]. Therefore its increment 
in obese women could underline the importance of this class of molecules 
for risk assessment of obesity-related morbidities and particularly of CVD. It 
must be stated that due to the similarity in the hydrophobic moiety and 
mass identity, Hexosylceramides (glucosylceramides and 
galactosylceramides) are not easily separated and quantified using a 
standard reverse-phase chromatography [316]. HexCers are represented in 
this work as the sum of detected glucosylceramides and 
galactosylceramides. Therefore observed changes are related to both 
molecules, and further studies will be needed to precisely identify the 
contribution of single glycosphingolipids to the total pool and the relative 
effect of different glycosphingolipids.  
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Figure 4. UPLC-MS analysis of sphingolipid alteration in sub-pooled sera samples from 
NWNL, NWDL and ODL men (Panel A); NWNL, NWDL and ODL women (Panel B). 
Tukey’s correction was employed after one-way ANOVA statistical analysis. Data are 
expressed in log scale and reported as mean ± SD. (*p-value < 0.05, **p-value < 0.01, ***p-
value < 0.001). 
 
Both NWDL and ODL men and women showed decreased levels of 
dihexcer, total and C24:1 compared to NWNL, respectively. These data 
suggest a protective role exerted by dihexCer that decrease in parallel in 
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obesity and dyslipidemia. Plasmatic dihexosylceramide was, in fact, found 
to be positively associated with anti-inflammatory cytokine IL-10 before and 
after adjustments for age, body fat and sex [317]. DihexCer levels were 
also found to be negatively associated with BMI in [310] and negatively 
associated with T2DM and prediabetic condition in both the San Antonio 
Family Heart Study and the Australian Diabetes, Obesity, and Lifestyle 
Study [318], confirming our results. 
To additionally increase the coverage of the sphingolipid profile of serum, 
S1P, and dhS1P levels, two sphingolipid newly associated with obesity 
[262] and usually not detected by standard LC-MS analysis, were 
investigated by LC-MS/MS following an MRM approach. 
In this case, Sph and S1P resulted unchanged in NWNL, NWDL and ODL, 
both men and women (Figure 5, A), while, on the other hand, dhS1P was 
significantly decreased in NWNL compared to both ODL and NWDL (figure 
5B). Data resulting from other sphingolipid classes compared in men and 
women are shown in Supplementary Figure 4. 
In obese and dyslipidemic normal-weight women, it can be postulated that 
increased levels of dhS1P (Figure 5, B), can be driven by the 
overexpression of SK1 and the following deviation of metabolic flux through 
the formation of dhS1P from dhSPh [319]. It is known that dhSPh is used 
for the production of more complex sphingolipids that it could be used for 
the catabolic generation of S1P. 
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Figure 5. MRM analysis of sphingoid bases alteration in sub-pooled sera samples from 
NWNL, NWDL and ODL men (A) and NWNL, NWDL and ODL women (B). Tukey’s 
correction was employed after one-way ANOVA statistical analysis. Data are expressed in 
log scale and reported as mean ± SD. (*p-value < 0.05, **p-value < 0.01, ***p-value < 
0.001). 
 
The precise biological functions of these dimorphic changes need to be 
further investigated to figure out if these data could provide a biological 
explanation and become a hint for personalized medicine. Also, in this 
case, there is a profound need for standardized methodologies and 
sampling to determine variation in this only apparently chemically simple 
class of molecules. 
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6.2. Andean subjects 
6.2.1. Biochemical and anthropometrical results 
Studies on Andean children born and living at San Antonio the Los Cobres, 
an Andean plateau located at 3775 mt above the sea level (a.s.l.), indicate 
a prevalence of dyslipidemia and hypertension compared to dwellers at 
lower altitudes, suggesting that despite similar food intake and daily 
activities, they undergo different metabolic adaptations [320]. This group of 
children is characterized by a prevalence of obesity and overweight of 8.1% 
[321] compared to the global population, in which the prevalence is 18% in 
children and adolescents [18] and Argentinean with a prevalence of 28.7% 
[322]. A report on children (aged 9.5±2 years) living in Buenos Aires 
indicates a prevalence of 29.7% for obesity and overweight [321]. The 
unexpected low prevalence of obesity and hypoxia are not the only 
characteristics of this group of subjects. Andean children show a peculiar 
dyslipidemic trait characterized by higher levels of TG (28% vs. 3.5%) and 
lower levels of HDL-C (30.0% vs. 5.5%) compared to children living in 
Buenos Aires [321]. Another study from San Pedro de Cajas (Peru) at 
4100m a.s.l. showed lower rates of HDL-C and high levels of TG in native 
populations [323], further confirming that dyslipidemic alterations are a 
characteristic trait in high altitude dwellers. Although in San Antonio de Los 
Cobres, the weather is generally sunny both in summer and winter [324], 
two recent studies identified Vit. D insufficiency or severe deficiency [325] 
[326], with levels of Vit. D lower than 7.94 ng/ml and with a Vit. D deficiency 
prevalence of 67.7% [327].  
The biochemical and anthropometrical parameters of the investigated 
group are summarized in Table 6, while p-values from biochemical and 
anthropometrical comparison can be found in supplementary Table 2. UW 
and OW groups showed acceptable mean levels of TC as indicated by the 
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National Cholesterol Educational Program [328], whereas borderline levels 
for total cholesterol (TC) were seen in NW and O. Mean levels of HDL-C 
were acceptable only in NW subjects. At variance, other groups were 
characterized by lower levels of HDL-C, classifying them as borderline 
[328]. Acceptable mean levels of LDL-C (lower than the 110 mg/dL cut-off), 
were detected in all groups. Conversely, borderline levels of mean 
triglycerides (TG) were seen in all groups except for O subjects that 
presented high levels [329]. Vitamin D was assessed, and the deficiency 
was present in all groups [298,327]. Blood sugar levels were beneath alert 
limits for all groups [329]. 
Table 6. Participant’s assessment of anthropometry and biochemical parameters. 
Characteristics are, if continuous, described using median and interquartile range or, if 
categorical, with counts and percentages. normally distributed data were analyzed by One 
way ANOVA with Bonferroni’s correction, otherwise Kruskal-Wallis’ with Dunn’s correction 
was adopted. (*t p-value for UW, 
+ 
p-value for NW 
+
, 
x 
p-value for OW, 
y 
p-value for O) *p-
value < 0.05, **p-value < 0.01, ***p-value < 0.001, 
+
p-value< 0.05, 
++
p-value< 0.01,
 +++
p-
value< 0.001, 
yy
p-value < 0.01. 
 
HDL-C was higher comparing NW vs. O (p-value < 0.01), instead the 
TC/HDL-C ratio was higher in O participants compared to UW and NW (p-
value < 0.05 and 0.01, respectively). HOMA-IR and insulin levels were 
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higher in O and OW subjects compared to NW (p-value < 0.01 and 0.05, 
respectively, in both comparisons). 
From the anthropometrical point of view, groups were homogeneous for 
age and sex. BMI was higher in OW and O group compared to UW and 
NW; thus, subjects were clustered in four main BMI groups. From the 
biochemical point of view, normal HDL levels were observed in NW only, 
whereas discrepant HOMA-IR parameters and insulin levels characterized 
OW and O, even though HOMA-IR and insulin values were beneath alert 
limits. All groups are characterized by a Vit.D deficiency and by a peculiar 
dyslipidemic trait with low levels of HDL-C or high levels of TG and TC. 
The investigated children have a higher prevalence of obesity and 
overweight (22% and 15.25% respectively) and a higher prevalence of Vit. 
D deficiency (100%) compared to previous reports [321]. The aim of the 
present study is to profile sphingolipids in different BMIs groups, 
independently from Vit. D. deficiency and dyslipidemic traits, to provide a 
molecular signature not only for obesity but also to identify molecules 
influencing their adaptation to high altitude hypoxia. 
6.2.2. Biochemical and lipidomic correlations  
Scatter plots for total Cers, total SMs, S1P levels and biochemical 
parameters are shown in Figure 6. The correlation table is shown in 
Supplementary Table 3. 
In UW subjects, the only correlation found was a between SMs levels and 
HDL-C (r = 0.854, p-value = 0.015). Regardless of the low number of 
correlation in the UW group, the association between HDL-C and SMs 
levels has already been described [330] [331] and is thought to be involved 
in reverse cholesterol transport. Several studies showed that increasing the 
content of SMs in HDL-C particle improved the import of cholesterol from 
erythrocyte membranes [332] and from non-cholesterol-loaded human skin 
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fibroblasts [333] to HDL-C. These data suggest that the overall relationship 
existing between SMs and HDL-C can contribute to explain, at least 
partially, the inverse correlation among HDL-C levels and risk of CVD 
development [331]. 
NW subjects are characterized by a higher number of correlations. Cers 
showed positive correlations with HOMA-IR (r = 0.389, p-value= 0.036), insulin 
(r = 0.418, p-value = 0.021), and TG (r = 0.379, p-value= 0.039). In the same 
group, a negative correlation with Vitamin D was also found (r = −0.4, p-value 
= 0.028). No correlation was found between SMs and biochemical parameters; 
nevertheless, a negative correlation (r = −0.375, p-value = 0.041) was 
identified between S1P and HDL-C. Particularly in normal-weight patients, 
ceramides correlate with several biochemical parameters strictly related to 
insulin resistance and T2DM. Even if insulin levels, glycaemia, and HOMA-IR 
parameters cannot be associated with T2DM and/or pre-diabetes, cers 
increase in parallel with insulin and HOMA-IR. The positive correlation 
between Cers and increasing levels of insulin-resistance could be associated 
with detrimental effects exerted by ceramides in insulin singling [200] and on β-
cell survival [334], increasing the risk of developing T2DM. 
In OW subjects correlations with biochemical parameters were positive for 
all sphingolipid species. Total Cers had a strong positive correlation with 
TC (r = 0.721, p-value = 0.005), LDL-C (r = 0.691, p-value = 0.024), as well 
as total SMs that strongly correlate with TC (r = 0.726, p-value = 0.005), 
LDL-C (r = 0.655,p-value = 0.015), and HDL-C (r = 0.603, p-value = 0.029), 
at last, S1P negatively correlated with LDL-C levels (r = −0.691, p-value = 
0.011). 
In overweight subjects, sphingolipids correlate with plasma lipid 
parameters, both for ceramides and SMs, confirming the relation between 
these two classes of lipids.  
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In O subjects, a single positive correlation links Cers and Glycaemia (r = 
0.683, p-value = 0.043). 
Our data did not allow us to figure out the causes behind these associations, 
that would have required, the assessment of enzymatic activity of several 
biological pathways as well as levels of SLs from tissue; nevertheless, results 
highlighted the strict association of sphingolipids not only with lipid 
parameters as TC, LDL-C HDL-C and TG but also with Vit. D and other 
biochemical parameters as HOMA-IR, insulin and glycaemia. 
Figure 6. Scatter plots for total Ceramide A, total sphingomyelin B, and total S1P C. X-Data 
for Cers, SMs, and S1P are in pmol/mL (log scale); Y-data for Vitamin D are in ng/mL, and 
Y-data for insulin are in μU/mL; Y-data for TG, TC, LDL-C are in mg/dL; r-value (Pearson’s 
correlation) p-values (two-tailed test). 
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6.2.3. UPLC-MS sphingolipid results 
In order to obtain complete information regarding differences on 
sphingolipid profiles, Cers (Figure 7), SMs (Figure 8), total 
dihydroceramides (dhCers), total hexosylceramides (HexCer), total 
dihexosylceramides (diHexCer), total monosialodihexosylganglioside 
(GM3), and total S1P levels (Figure 9) were assessed and compared 
between groups characterized by different BMIs. Cers acyl chains: 
d18:1/16:0, d18:1/22:0, and d18:1/24:0 (Figure 7), and SMs d18:1/18:0, 
d18:1/20:0, and d18:1/22:0 (Figure 8) were also investigated. 
Total Ceramides were found to be higher in NW compared to both UW and 
OW (p-value, < 0.01 and 0.001) subjects, and in O and UW compared to OW 
(p-value < 0.001 and 0.05). Cers acyl chains (d18:1/16:0, d18:1/22:0, and 
d18:1/24:0) presented a similar trend as total Cers. 
Specifically, Cer (d18:1/16:0) was higher in UW, NW, and O subjects 
compared to OW (p-value < 0.05, p-value <0.001 and p-value < 0.001). Cer 
(d18:1/22:0) interestingly followed the same pattern as Cer (d18:1/16:0) in 
NW (p-value < 0.001) and O (p-value < 0.001) compared to OW, but UW 
subjects in this case were characterized by lower levels of Cer (d18:1/22:0) 
compared to NW (p-value < 0.01). Ceramide (d18:1/24:0) levels resulted in 
a trend identical to the one obtained from total Cers, showing higher levels 
in NW subjects compared to UW and OW (p-value < 0.05 and p-value < 
0.001). O and UW had higher levels of Cer (d18:1/24:0) in the OW 
comparison (p-value < 0.001 and p-value < 0.05). 
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Figure 7. UPLC-MS results for total ceramides A, Cer (d18:1/16:0) B, Cer (d18:1/22:0) C, 
and Cer (d18:1/24:0) D. Results are in pmol/mL in Log scale; p values are expressed as * p-
value < 0.05, ** p-value < 0.01, and *** p-value < 0.001. 
 
The comparison between dyslipidemic Vit. D deficient NW subjects and 
their O counterparts, confirmed data from Saudi Arabian subjects, showing 
that NW and O dyslipidemic subjects, independently from their BMI, 
develop similar levels of cers. However, it must be acknowledged the fact 
that comparisons or parallelisms among different populations must be 
undertaken with caution because of the profound differences present in 
terms of genetics, age, and environmental characteristics.  
The pattern seen for Ceramides was reversed in sphingomyelins, in fact, 
total SMs (Figure 8) showed higher levels in OW compared to both O and 
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NW subjects (p-value < 0.01 and p-value < 0.001), and lower levels in NW 
compared to UW (p-value < 0.01). 
As for Cers acyl chains, SMs acyl moiety followed the same trend seen for 
total SMs. SM (d18:1/18:0) was found to be higher in OW subjects 
compared to both NW (p-value < 0.001) and O (p < 0.01). NW and O group 
showed for SM (d18:1/20:0) decreased level when compared to OW (p-
value <0.001 and p-value <0.001, respectively). SM (18:1/22:0) behaving 
as SM (d18:1/20:0) for the NW and O comparison with OW (p-value <0.001 
and p-value <0.001, respectively), highlighted differences also in the UW 
vs. NW comparison, where higher levels were present in the UW group (p-
value < 0.001). The UW group was also characterized by lower levels of 
this acyl chain when compared to OW (p-value <0.001).  
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Figure 8. UPLC-MS results for total sphingomyelins A, SMs (d18:1/18:0) B, Cer 
(d18:1/20:0) C, and Cer (d18:1/22:0) D. Results are in pmol/mL in Log scale; p values are 
expressed as ** p-value < 0.01, and *** p-value < 0.001. 
 
For total dhCers (Figure 9), the same tendency seen in Cers was observed. 
Higher levels of dhCers were seen in NW and O subjects when compared 
to the OW group (p-value < 0.001 in both comparisons). MRM analysis of 
S1P revealed a clear trend for decrement across different BMI percentiles 
in S1P levels. In this case, statistically significant differences were seen 
when comparing NW vs. O (p-value < 0.05), and UW vs. O (p-value < 
0.05). 
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Glycosphingolipids: HexCer, diHexCer, and GM3 (Figure 9) showed a clear 
and characteristic pattern. NW patients had, in fact, higher levels of those 
SLs species compared to UW (p-value < 0.001). For total HexCer, NW 
subjects also showed a higher level when compared to OW and O (p-value 
< 0.05 and 0.001, respectively). Total diHexCer levels in O were lower if 
compared to NW (p-value < 0.001), while UW subjects had lower levels in 
the OW comparison (p-value < 0.05). At last, total GM3 was found to be 
higher in NW compared to OW (p-value < 0.01) and O (p-value < 0.05) 
subjects. GM3 was also higher in the OW and O vs. UW comparison (p-
value < 0.05 in both comparisons). 
Figure 9. UPLC-MS and MRM results for total dhCers A, S1P B, total HexCer C, total 
dihexCer D, and total GM3 E. Data are in pmol/mL in Log scale; p values are expressed as * 
p-value < 0.05, ** p-value < 0.01, and *** p-value < 0.001. 
 
Figure 10 summarizes glyco/sphingolipid levels in the analyzed groups and 
highlights that UW and O subjects have similar glyco/sphingolipids levels, 
with S1P at variance, being high in UW and low in O subjects. 
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Figure 10. Summary of glyco/sphingolipid levels and altered ceramide-biosynthesis 
pathways in UW and O. Different size arrows indicate the different involvement of Cers 
biosynthetic pathways in UW and O. LC-MS and LC-MS/MS results for total Cers, total 
dhCers, total SMs, total HexCer, total dihexCer, and total GM3. Data are expressed as 
pmol/mL in Log scale; p values are expressed as * p-value < 0.05, ** p-value < 0.01, and *** 
p-value < 0.001. 
 
It can be hypothesized that Cers levels in the O and UW groups originate 
from de novo biosynthesis, as dhCers levels are comparable to NW group. 
The main discrepancy in SLs profiles between the four different groups 
relied on S1P levels that were high in UW and NW, whereas low in OW and 
O groups. Regarding S1P, a recent study from Sun et al. demonstrated that 
an increment in erythrocytes S1P levels, follows high altitude hypoxia 
exposure and that S1P stimulated the oxygen release capacity of 
erythrocytes by increasing cytoplasmatic 2,3-biphosphoglycerate [335], a 
specific glycolytic intermediate that facilitates O2 release [336]. 
It is possible to speculate that UW and NW children showed a better 
metabolic adaptation to high altitude hypoxia due to their high constitutional 
levels of S1P that allow the activation of RBC glycolysis and a better 
release of O2 from red blood cells to tissues reducing cell hypoxia and 
HIF1-α activation. The latter is known to be a lipogenic inducer, directly 
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inducing PPARγ and fatty-acid-binding proteins (FABP) [337–339]. 
Conversely, obese children with reduced levels of S1P were unable to 
adapt to oxygen lack due to their poor S1P-mediated O2 release and they 
can undergo a constitutive activation of HIF1-α, causing accumulation of 
lipids, due to both HIF1-α induced lipogenesis/lipotoxicity and ceramide 
mediated lipotoxic effects [203,340,341]. 
UW and O children were also characterized by low levels of 
glycosphingolipid. The activation of Neuraminidase 3 sialidase (NEU3) in 
transgenic mice causes reduced tissue and circulating levels of GM3 [342]. 
From a previous study from our group performed on animal models 
exposed to prolonged severe hypoxia, NEU3 was increased [343]. In the 
present study, the decrease in GM3 levels could be associated with the 
activation of NEU3 sialidase, which has been recently described as a target 
of HIF2 alpha and thus regulated by hypoxia [344]. 
The restricted number of subjects and the lack of a verification study are 
the two major drawbacks of this study. The assessment of 2,3-BPG, pH, 
partial pressure of oxygen/carbon dioxide, and haemoglobin-O2-saturation 
will, however, be undertaken in a separate study to determine the 
anomalous metabolism and consequent O2 affinity in erythrocytes. 
Not only parameters regarding hypoxia adaptation and O2 affinity but also 
RNAs from peripheral blood mononuclear cells for the quantitative 
assessment of enzymes involved in SLs biosynthetic pathways and of 
circulating cytokines or adipokines will be collected and presented in a 
separate study. 
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7. CONCLUSIONS 
The novelty introduced by our study on Saudi Arabian serum samples is 
the identification of specific Cers acyl chains associated with obesity and 
the impact of sexual dimorphism on circulating SLs independently from 
serum dyslipidemia and Vit. D status. Notably, recent results obtained in 
normal-weight subjects indicated that gender is associated with several 
plasma sphingolipids like Cers, SMs, and diHexCer, fostering our results 
[310]. 
Our study confirms previous observations, indicating that Cers levels are 
increased in ODL compared to NWNL [345]. Furthermore, our data 
highlighted that Cers are significantly higher not only in ODL but also in 
NWDL, indicating a direct association between dyslipidemia, Vit. D 
deficiency and Cers circulating levels. Results from Saudi Arabians, 
identified alterations in specific Cers, SMs, and dhSMs acyl chains, 
providing not only a signature for obesity, independently from dyslipidemia 
and Vit. D deficiency, but also an indication of the relevance of SLs’ acyl 
chains variations rather than changes on “total SLs species”, where 
information from single bioactive acyl moiety could be lost.  
The study of Andean children, born and living at altitude, indicated the 
same dependency of Cers and SMs on Vit. D deficiency and dyslipidemia 
[346], supporting our previous results. Noteworthy, the correlation identified 
in Andean children between Cers, SMs, S1P and plasma lipid/Vit. D levels 
confirmed this association. Results indicate that UW and O Andean 
children, although a common dyslipidemic trait, are characterized by a 
common SLs profile with similar levels of dhCer, SMs, HexCer and 
diHexCer. Regarding S1P, UW and NW subjects compared to O showed a 
higher level of S1P not observed in the O group. It can be speculated that 
UW and NW children utilizing S1P can activate the same biochemical 
pathway promoting oxygen delivery to maintain energy production and 
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homeostasis, therefore resulting in a more fit phenotype. By contrast, O 
children, showing lower levels of S1P, display reduced O2 delivery to 
tissue, resulting in a less adapted phenotype prone to the activation of 
lipogenic and lipotoxic pathways. Further data based on 2,3-BPG, pH, 
partial pressure of carbon dioxide (PCO2), of oxygen (PO2), and 
haemoglobin-O2 saturation (SO2) will be necessary to determine the 
abnormal O2 affinity or altered metabolism of RBC. Studies in this direction 
are ongoing aimed to open new avenues in the complex field of hypoxia 
tolerance in high-altitude dwellers. 
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9. SUPPLEMENTARY MATERIAL 
Supplementary File 1: 
Sphingolipid identified and quantified in Saudi Arabian subjects. 
All SLs species cited in this file were identified and precisely quantified. For statistical 
analyses, single lipid species quantities were summed to obtain total class levels.  
Total Cer was obtained as the sum of Cer (d18:1/14:0), Cer (d18:1/16:0), Cer (d18:1/18:0), 
Cer (d18:1/18:1), Cer (d18:1/20:0), Cer (d18:1/20:1), Cer (d18:1/22:0), Cer (d18:1/22:1), Cer 
(d18:1/24:0), Cer (d18:1/24:1) and Cer (d18:1/24:2). Total dhCer was obtained as the sum 
of dhCer (d18:0/16:0), dhCer (d18:0/18:0), dhCer (d18:0/22:0) and dhCer (d18:0/24:0). Total 
sphingomyelin was obtained as the sum of SM (d18:1/14:0), SM (d18:1/14:1), SM 
(d18:1/16:0), SM (d18:1/16:1), SM (d18:1/18:0), SM (d18:1/18:1), SM (d18:1/20:0), SM 
(d18:1/20:1), SM (d18:1/22:0), SM (d18:1/22:1), SM (d18:1/24:0), SM (d18:1/24:1), SM 
(d18:1/24:2) and SM (d18:1/24:3). Total dhSm was obtained as the sum of dhSM 
(d18:0/14:0), dhSM (d18:0/16:0), dhSM (d18:0/18:0), dhSM (d18:0/20:0), dhSM (d18:0/22:0) 
and dhSM (d18:0/24:0). Total hexCer was obtained as the sum of HexCer (d18:1/16:0), 
HexCer (d18:1/22:0), HexCer (d18:1/24:0) and HexCer (d18:1/24:1). Total dihexCer was 
obtained as CDH (d18:1/14:0), CDH (d18:1/16:0), CDH (d18:1/18:0), CDH (d18:1/22:0), 
CDH (d18:1/24:0) and CDH (d18:1/24:1). 
Sphingolipid identified and quantified in Andean subjects.  
All SLs species cited in this file were identified and precisely quantified. For statistical 
analyses, single lipid species quantities were summed to obtain total class levels.  
Total Cer was obtained as the sum of Cer (d18:1/14:0), Cer (d18:1/16:0), Cer (d18:1/18:0), 
Cer (d18:1/18:1), Cer (d18:1/20:0), Cer (d18:1/20:1), Cer (d18:1/22:0), Cer (d18:1/22:1), Cer 
(d18:1/24:0), Cer (d18:1/24:1) and Cer (d18:1/24:2). Total dhCer was obtained as the sum 
of dhCer (d18:0/16:0), dhCer (d18:0/22:0), dhCer (d18:0/24:0) and dhCer (d18:0/24:1). Total 
sphingomyelin was obtained as the sum of SM (d18:1/14:0), SM (d18:1/14:1), SM 
(d18:1/16:0), SM (d18:1/16:1), SM (d18:1/18:0), SM (d18:1/18:1), SM (d18:1/20:0), SM 
(d18:1/20:1), SM (d18:1/22:0), SM (d18:1/22:1), SM (d18:1/24:0), SM (d18:1/24:1), SM 
(d18:1/24:2) and SM (d18:1/24:3). Total dhSm was obtained as the sum of dhSM 
(d18:0/14:0), dhSM (d18:0/16:0), dhSM (d18:0/18:0), dhSM (d18:0/20:0), dhSM (d18:0/22:0) 
and dhSM (d18:0/24:0). Total hexCer was obtained as the sum of HexCer (d18:1/16:0), 
HexCer (d18:1/22:0), HexCer (d18:1/24:0) and HexCer (d18:1/24:1). Total dihexCer was 
obtained as CDH (d18:1/14:0), CDH (d18:1/16:0), CDH (d18:1/18:0), CDH (d18:1/22:0), 
CDH (d18:1/24:0) and CDH (d18:1/24:1). Total GM3 was obtained as the sum of GM3 
(d18:1/16:0), GM3 (d18:1/18:0), GM3 (d18:1/20:0), GM3 (d18:1/22:0), GM3 (d18:1/24:0) and 
GM3 (d18:1/24:1).  
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Supplementary Table 1: p-values from One-way ANOVA comparison after Bonferroni’s 
correction (bold) or after Dunn’s correction (regular).  
 
Supplementary Figure 1. (A) calibration curve of Cer (d18:1/16:0) resulting from 3 different 
HPTLC separation performed in three different days. (B) calibration curve of LacCer 
(d18:1/17:0) resulting from 3 different HPTLC separation performed in three different days. 
(C) limit of detection (LOD) were set at 44 pmol for Cer (d18:1/16:0) and at 18 pmol for 
LacCer (d18:1/17:0) (D). 
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Supplementary Figure 2. Non statistically significant results from Cers (C20-24) and SMs 
(C20-24) by HPTLC-Primuline profiling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
112 
 
Supplementary Figure 3. UPLC-MS analysis of Cers, dhCers, SMs and dhSMs, acyl 
chains from NWNL, NWNL and ODL men (A, C, E and G) and from NWNL; NWDL and ODL 
women (B; D; F; H).  
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Supplementary Figure 4. Non statistically significant results from UPLC-MS analysis of 
Cers, dhCers, SMs, dhSMs, HexCer and dihexCers acyl chains from NWNL, NWDL and 
ODL men and women. Non statistically significant results from MRM analysis of Sph, S1P 
and dhS1P from NWNL, NWDL and ODL men and women.  
 
Supplementary Table 2. P-values from One-Way ANOVA comparison after Bonferroni’s 
correction (regular) or after Dunn’s correction (bold)  
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Supplementary Table 3. P-values from two-tailed test, r-values from Pearson’s correlation 
(regular), or Spearman’s correlation (bold).  
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